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ABSTRACT
DEVELOPMENT OF PRE-CLINICAL ASSAYS BASED ON TANDEM MASS SPECTROMETRY TO
INVESTIGATE GABAA RECEPTOR MODULATORS
by
Margaret L. Guthrie
The University of Wisconsin – Milwaukee, 2017
Under the Supervision of Professor Alexander (Leggy) Arnold

Drugs are compounds that interact with a biological system to produce a specific
biological response. The goal of drug discovery is to design and synthesize a pharmaceutical
agent that will produce a desired biological effect. However, the in-vivo effects of a drug
molecule cannot be predicted without a variety of test results prior to human clinical trials. In
order to designate any drug compound as a leading candidate (or “lead” compound), it needs
to show significant pharmacological activity, maintain a desirable metabolic half-life, and
display minimal side effects and toxicity. Several in-vitro and in-vivo pre-clinical assays have
been developed to measure metabolic parameters and aim to qualify, or rule out, compounds
based on drug distribution within the body. The developments of these assays are presented
herein.
First, an assay was developed to estimate metabolic half-life of drug compounds in vitro
using human and mouse liver microsomes by liquid chromatography-mass spectrometry (LCMS).

Secondly, a method for determination of pharmacokinetic (PK) parameters was

developed and optimized using absolute quantitation by LC-MS/MS. Thirdly, metabolic stability
was further estimated in cell suspensions and tissue homogenates, specifically using HepG2
ii

cells as a model for hepatocytes, and rat brain as a model for illustrating stereochemical
specificity within the brain enzymatic metabolism. Finally, to visualize the spatial distribution of
small molecules in-vivo, matrix assisted laser desorption ionization tandem mass spectrometry
(MALDI-MS/MS) was employed to image the distribution of drug compounds in whole tissue
slices. By employing a variety of mass spectrometric techniques, we have been able to both
assess the viability and follow the distribution of lead compounds from in-vitro sub-cellular
fractions to whole cells through whole tissues and carry out in-vivo studies.
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CHAPTER 1. INTRODUCTION
1.1

Introduction to Drug Discovery
The successful introduction of a new therapeutic treatment into the marketplace is a

time consuming and expensive endeavor, one which is estimated to take more than 8 years and
$500 million dollars.2 Before a novel treatment can reach clinical trials, it must withstand a
myriad of pre-clinical assays, and show efficacy to treat the disease, display selectivity to the
intended target molecule or target organ, and yield limited adverse side effects. The ability to
exclude underperforming lead compounds in a high throughput and cost effective manner is
crucial to the field of drug discovery. The development of a new pharmaceutical product occurs
in several stages. Some general stages include target identification, drug compound discovery,
investigational new drug application, clinical trials, and commercialization. Firstly, the biological
target mediating the disease must be verified. This can be a protein target, such as an enzyme
or receptor, or a nucleic acid target, such as DNA. The drug discovery process then moves to the
identification of an initial lead compound, which has been identified as a promising candidate
to treat the disease by way of acting at the established drug target. Usually this strategy
involves a high throughput screening method or rational drug design. Typically, the initial lead
compound will require structural modifications to improve binding, reduce adverse side effects,
and to produce the maximum desired pharmacological effect. Changes in the structure of a
drug compound, as well as changes to the method of administration (oral dosing, inhalation, or
injection), will impact the biological effects to the test subject. The assays presented herein are
designed to aid in the drug discovery process after an initial lead has been identified, by
measuring parameters that impact important drug properties. A general outline for the drug
discovery and development process is presented in Figure 1.
1

The study of how a drug is absorbed, distributed, metabolized and excreted (generally
abbreviated as ADME) is a vast field in drug discovery as it characterizes important drug-like
properties of a lead compound.1 The term ‘ADMET’ is often used as well to describe toxicity in
addition to the other terms, which is an important consideration because drugs that are not
undeniably safe will not become commercial drugs. It is important to understand the
movement of a drug within the body and how the body processes a drug. In this work, assays
are presented using mice to ascertain such information. However, before a compound can
advance to in vivo experiments with animals, it should be characterized by inexpensive, rapid,
efficient and high-throughput in vitro assays. These assays are presented first and foremost in
the upcoming chapters.

Eliminate

Figure 1. General outline of the drug discovery process from target inception to market.3
2

Both in vitro and in vivo assays have been developed by the Arnold Group embedded in
the Milwaukee Institute for Drug Discovery to characterize synthesized drug candidates at
UWM and in collaboration with other universities and companies. The goal of these
collaborative projects is to move a lead compound forward into clinical trials, ideally creating a
novel treatment for a selected disease target (such as asthma, cancer, neuropathic pain,
depression, and many others). The assays assist medicinal chemists within the MIDD to
determine if structural modifications can be made to lead compounds to increase desirable
drug-like properties of the molecule. These properties include bioavailability, metabolic
stability, and absence of toxicity. Figure 2 illustrates characteristics of drug compounds that
should be optimized, as well as characteristics that should be avoided when designing a new
drug. The assays developed herein have kept these properties in mind and aim to answer
questions regarding these characteristics.

3

Figure 2. Criteria for optimization of lead compounds in drug development.4

There are some general guidelines that medicinal chemists follow to aid in improving a
drug candidate with regard to the above criteria. One such guideline is Lipinski’s Rules of Five.5
These rules include avoiding molecules with more than five hydrogen bond donors, molecular
weights over 500, octanol-water partition coefficients (logPo/w) greater than five, or a sum of
nitrogen and oxygen atoms (within the molecule) above ten. Typically molecules that do not
obey these general rules will display poor ADME properties.5-6 It is important for a drug
candidate to display optimum ADME characteristics, as compounds that are not stable in the
body (whether they are excreted too quickly or readily metabolized into other compounds) may
not have the desired pharmaceutical effects. Not only must a compound be stable upon
entering the body, it also must be relocated to its target tissue after absorption into the

4

bloodstream. For example, in our pursuit to treat asthma, it is important to verify that the
compound reaches the lung, as it is the target organ. Drug distribution refers to the relocation
of the drug from blood to the various tissues in the body, and the rate at which it occurs is an
important ADME property.7
Once the drug has been distributed to the target location, the body will clear the drug
by two general pathways; metabolism and excretion. Understanding the metabolism of highly
lipophilic molecules is important, because these molecules will typically undergo
biotransformation into a readily excreted polar metabolite.8 Many xenobiotics, or compounds
that are exogenous to the body, are cleared this way. Large lipophilic molecules will be
converted to more water-soluble products before renal elimination.

The liver will also

participate in the excretion process via the bile duct.7 In vitro assays can be conducted to
estimate the uptake of a compound into cells (for example, in hepatic cells), but this does not
necessarily equate directly to excretion, as there are many processes that occur after a drug has
been taken up into a cell.9 Therefore, renal and fecal excretions are studied in vivo because in
vitro assays do not emulate these processes well.6 For this reason, the excretion portion of
ADME has not been extensively studied in this work.
1.2

Drug Target: GABAA Receptor
The molecular target that has been identified for all lead compounds tested herein is

the GABAA receptor (GABAAR). GABA (1,4-aminobutanoic acid, or γ-aminobutryic acid) is the
major inhibitory neurotransmitter in the brain that influences neurons via a large number of
receptors, which are grouped based on their pharmacology (A, B, or C). The GABA A and GABAC
receptors are ligand-gated ion channels, whereas the GABAB receptor is a G-coupled protein
5

receptor. The target for the following studies is the GABAAR. In particular, the GABAAR has been
extensively studied due to the variety of modulators that act on this receptor, including
benzodiazepines, ethanol, general anesthetics, and barbiturates.10

Figure 3. GABAA receptor.11

The majority of the compounds investigated herein are novel GABAAR subtype-selective
imidazobenzodiazepine scaffold as displayed in Figure 4. Both, non-selective benzodiazepines
and selective imidazobenzodiazepine are allosteric modulators, which bind at a topographically
distinct site from the endogenous ligand GABA and potentiate or inhibit the activity of that
ligand (e.g. binding or signaling).12

6

Figure 4. Structures of benzodiazepines.

During the development of selective GABAAR modulators, these compounds have been
crucial to identify the pharmacology of different GABAAR subtypes. The subtype selectivity of
ligands

was

achieved

by

changing

their

substitution

patterns.

Most

of

the

imidazobenzodiazepines obey Lipinski’s Rules of Five and have good ADME properties. In
addition, they contain many heteroatoms that make them well suited for analysis by mass
spectrometry.
1.3

Instrumental Techniques
A mass spectrometer is an analytical instrument used to identify and quantify analytes

based on their mass-to-charge ratio (m/z). In combination with our assays, these instruments
enable accurate, rapid, and reproducible ADME results. The analytical methods presented
herein are designed for inexpensive, high-throughput analyses to gain a lot of ADME
information in a short period of time. Mass spectrometry is both sensitive and selective,
making it an ideal method by which to analyze compounds in complex biological matrixes.
Tandem mass spectrometry (MS/MS) refers to ion selection, fragmentation, and detection, and
employs multiple mass analyzers within one instrument. MS/MS allows for the absolute

7

quantification of analytes in these complex sample types. In addition, high resolution mass
spectrometry can determine the exact mass of compounds that enable exact molecular formula
determination. This is especially important for metabolite identification. Although this work
does not focus heavily on metabolomics, strategies for doing such shall be discussed. Lastly,
imaging mass spectrometry enables the visualization of the analyte spatially within whole tissue
slices retrieved from animals dosed in vivo. This cutting-edge technology is gaining prominence
in modern drug discovery and clinical settings. The instrument-based assays outlined herein
determine the drug-like properties of analytes from the sub-cellular and cellular in vitro level to
tissues and overall characteristics in vivo.
1.3.1 High Performance Liquid Chromatography
The first analytical technique employed in our analyses is high-performance liquid
chromatography (HPLC). HPLC is a versatile and widely used separation technique employed in
drug analysis to ascertain purity, quantify amounts of compound in biological samples, separate
components of complex biological matrixes and a myriad of other applications. The sample, as a
mixture of solutes, is contained in a liquid solvent and separated on a stationary phase via one
of several possible retention mechanisms, including partitioning, adsorption, ion-exchange,
size-exclusion, affinity, or chiral chromatography.13 The separations achieved with HPLC for this
work were generally achieved by either partitioning mechanisms or adsorption. HPLC is often
coupled to mass spectrometry to form a combination technique known as LC-MS, separating
the analytes first by chromatography and then using the mass spectrometer as detection
system. LC-MS is a core technique used in chemical analysis within the drug discovery arena, as
well as many other fields. For drug discovery, many drug compounds are hydrophobic and

8

therefore well retained and may be separated by common stationary phases with HPLC.
Similarly, many drug compounds have functional groups, such as amines, that can aid in the
detection by mass spectrometry. Drug molecules in large part are inherently amenable to LCMS analysis based on the physical properties of their chemical structure.
The history of chromatography dates back to Mikhail Tswett, a Russian botanist. Tswett
fathered the idea of adsorption chromatography by postulating that chlorophyll was retained
by some molecular forces on the leaf (yielding the green color) and that is why he struggled to
extract the compound with petroleum ether. He developed a technique to separate plant
pigments, such as chlorophylls and xanthophylls, by using a calcium carbonate stationary phase
and a diethyl ether mobile phase. He published this work in 1906 in Berichte der Deutschen
Botanischen Gesellschaft, 24, 384.14 Tswett separated these plant pigment species as colored
bands and coined the term ‘chromatogram’ as a junction of the Greek ‘chroma’, meaning color,
and ‘graphein’, meaning writing.13
Decades later, in 1952, Martin and Synge further defined the separation mechanisms at
work in chromatography (and, invented gas chromatography) with the idea of theoretical
plates.15 In this theory, which in part won them the Nobel Prize, the chromatographic column is
envisioned as a series of many layers. These hypothetical layers exist orthogonally to the
direction in which the analyte is moving, thereby playing a role in separation of the analytes as
they “migrate through” the layers. According to this theory, with every theoretical plate,
equilibration of the solute between the stationary and mobile phase occurs (however, in reality,
a true ‘equilibrium’ is never reached between the stationary phase and the mobile phase). The

9

thickness of each of these layers is called the height equivalent to the theoretical plate (HETP,
H). The number of theoretical plates (N) is equivalent to the ratio of the column length (L) to
the plate height (N = L/H), and varies with any given column.

This theory within

chromatography describes the separation of analytes as being improved by increasing the
number of theoretical plates.16 The height of the theoretical plate can be described by Equation
1, the van Deemter equation.
𝐻 =𝐴+

𝐵
ū

+ 𝐶ū

Equation 1.

The van Deemter equation is a well-known model to chromatographers as a way to
estimate the number of theoretical plates and to understand sources of band broadening.17
Each variable in this equation impacts the chromatography, and can be used to illustrate
challenges in chromatographic separations. The ‘A’ variable refers to eddy diffusion, which
describes movement through a non-ideal packing material for the solid phase. Particularly in
the early days of chromatography, stationary phases were quite roughly prepared and the
particles packed within the column were far from uniform. The ‘B’ term refers to longitudinal
diffusion, or how particles elute in the lengthwise direction of the column. The ‘C’ term
describes the resistance of the analyte to mass transfer between the mobile phase and the
stationary phase. The interaction between the analyte with respect to both phases is a key
aspect of chromatographic separations, however that does not mean that these interactions
are without flaws. The ‘u’ term refers to the linear velocity.16a The average of these plots shown
as plate height vs. flow velocity can be seen in Figure 5.
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Figure 5. Visual representation of the components of the Van Deemter equation, a plot which aids in
describing theoretical plate height.

The basic components of an HPLC system are shown in Figure 6. The main components
include a solvent reservoir (typically 1L glass bottles), binary pump system, an injector (which
can be automated or manual), an analytical column, and the detector. The detector for many
HPLC systems is a molecular absorption spectrometer, such as a photodiode array (PDA). Many
compounds are detectable in the ultraviolet range. Although the analytes that can be detected
by UV are vast, the limits of detection are typically much lower for MS, therefore this work did
not utilize UV detection systems. Other minor components include an inlet and in-line solvent
filters, sample filters, pre-column filters (or “guard columns”), and a back-pressure regulator.18
In recent years, ultra-high pressure HPLC (or UHPLC) has become much more common, allowing
for much higher pressures and less of a need to regulate the pressure to a lower value. This is
advantageous for greater peak resolution, shorter analysis times, and the ability to separate
complex mixtures. The LC-MS analyses presented herein were all performed using UHPLC,
which is desirable for drug discovery applications because of the short analysis time.
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Figure 6. Basic schematic of HPLC.

As illustrated in the Figure 6 above, the HPLC system begins with solvents from a
reservoir, which are filtered with an inlet solvent filter to remove particulates. The solvents are
pumped to the analytical column, and on the way the flow passes an injection valve.18 The
injection valve is equipped with a sample loop (50 µL) and either a manual valve or, more
commonly, an autosampler, which is preferred for high-throughput analyses. The sample loop
allows for the repeatable introduction of sample into the flow path. The sample is then
separated on the analytical column based on the attraction of the sample components between
the solvent (i.e., the mobile phase) and the packing material (i.e., the stationary phase) within
the column.18

12

1.3.2 Mass Spectrometry
Mass spectrometry (MS) is a technique used to study molecules or fragments of
molecules, which are separated and analyzed based on their mass-to-charge (m/z) ratio.
Current techniques in MS involve the creation of ions in the gas phase, generally from more
condensed phases (although not always, as is the case for gas chromatography mass
spectrometry, GC-MS). A general scheme of the components of a mass spectrometer is
presented in Figure 7. First developed by Francis W. Aston in 1919, it was originally employed to
separate isotopes of neon onto a photographic plate and contributed to his award of the Nobel
Prize in 1922.19

Figure 7. Block diagram of features of a typical mass spectrometer.20

MS is often used as a detector following chromatography and can garner both
qualitative and quantitative information with a high level of sensitivity and selectivity. As
described in the HPLC section above, the sample is injected and pumps are used to migrate the
sample though separation on the analytical column. When MS is used in conjunction with HPLC,
the pumps then pump the eluate from the analytical column to the ionization source. Ions are
generated in the gas phase and are then separated by m/z ratio via the mass analyzer. There
are several ionization methods for LC-MS, the most common of these being electrospray
ionization (ESI) and atmospheric pressure chemical ionization (APCI). Mass analyzers used to
13

separate ions by mass include the very commonly used quadrupole, ion trap, and time-of-flight
mass analyzer. Finally, a detector is employed such as an electron multiplier tube, and the
information generated is processed and stored on a computer. A general schematic of LC-MS
instrumentation is shown in Figure 8.

Figure 8. Schematic diagram of a mass spectrometer with HPLC as the sample introduction system.21

There are many other ionization methods available to generate gas phase ions for mass
spectrometry, such as electron impact (EI) and chemical ionization (CI), which are the oldest
methods and employ a gas phase sample introduction. This work has utilized exclusively
ionization methods compatible with more condensed phases, namely evaporative ionization
methods (ESI, APCI), and also desorption from solid phase samples by matrix-assisted laser
desorption ionization (MALDI). Schematic representations of these methods are illustrated in
Figure 10, Figure 11, and Figure 12, respectively.
3.2.1 Ionization Methods
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ESI as an ionization method for mass spectrometry was first published by John B. Fenn
in 1988.22 A high voltage is applied to the capillary wire, while the eluent is pumped through the
capillary, creating a very fine mist. Droplets become highly charged, and the positive charge of
the droplets is repelled from the positive charge of the capillary.19 As the electrostatic repulsion
exceeds the surface tension, a coulombic explosion occurs releasing ions into the gas phase.
Meanwhile, the charge density at the surface of the droplets increases as the solvent is heated
and evaporated (this occurs at the critical point, known as the Rayleigh stability limit). The
instrument is operated under high vacuum and so ions and neutral molecules in the gas phase
are drawn through the entrance cone and toward the mass analyzer. 21 ESI can yield sample ions
with multiple charges, which can be advantageous when working with larger molecules, in
order to yield a mass-to-charge ratio (m/z) within the detection range of the mass analyzer.

Figure 9. Schematic representation of ESI.13
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Figure 10. Positive ion generation mechanism by ESI.21

APCI also contains a heated vaporizer, which facilitates the rapid desolvation and
vaporization off the droplets that are sprayed from the capillary. Reagent ions are generated
from this solvent vapor by a corona needle discharge, which is created with a constant current
between 2 and 10 µA leading to the formation of ions. The energized electrons produced by
the corona discharge ionize the flowing nitrogen gas by primary ion formation. Ionized nitrogen
reacts with solvent molecules, forming solvent ions through secondary ion formation. Solvent
ions react via a proton transfer with the sample molecules to form sample ions [M+H] +.
Chemical ionization is an efficient method due to the numerous ion-molecule collisions. As with
other ionization methods, charged ions and neutral molecules in the gas phase are drawn
through the entrance cone by vacuum and travel to the mass analyzer. 21 APCI yields singlycharged sample ions and is therefore limited to molecules with masses up to about 2000 atomic
mass units (amu). However, APCI can allow for the ionization of less polar compounds, and can
sometimes be a more efficient method of ionization than ESI depending on the analyte. In
addition, on some instruments (including the Shimadzu LC-MS instruments employed in this
work), APCI can be used in conjunction with ESI (known as DUIS mode).

16

Figure 11. Positive ion generation mechanism by atmospheric pressure chemical ionization.21

Although ESI and APCI are the most common soft ionization techniques seen in LC-MS,
these ionization methods are only appropriate for samples in the liquid state. Samples in the
solid state require another ionization technique, and one such example is matrix-assisted laser
desorption ionization, or MALDI. To create ions by MALDI, analytes are dried on a solid
conductive surface, usually a metal plate, and coated with a matrix, which will then cocrystallize with the analyte. A laser is fired at the sample surface and the matrix absorbs the
energy that enables both analyte and matrix to desorbed from the surface creating an ion
plume. The exact mechanism of the formation of this ion plume is not completely understood,
but it is thought that the matrix absorbs energy from the laser and transfers that energy to the
analyte. It is also believed that the analyte is desorbed as a neutral molecule and ionized by
proton transfer from protonated matrix ions. MALDI is the method of choice for larger
molecules such as proteins and peptides, and is employed to ionize dry solid samples into the
gas phase.
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Figure 12. Cartoon representation of MALDI.13

3.2.2. Mass Analyzers
In addition to the variety of ionization methods employed in this work, there are also
several different types of mass analyzers employed based on the type of analysis performed.
The mass analyzers used predominantly in this work are the quadrupole and time-of-flight mass
analyzers. The most common type of mass analyzer seen is the quadrupole mass analyzer. This
mass analyzer is an inexpensive mass filter consisting of four cylindrical rods. A constant DC
voltage is applied to the rods modified by a radio frequency. The four rods create a “tunnel”
where the ions are introduced, and only ions with a certain m/z possess the stable trajectory
necessary to pass through the quadrupole to the detector (as shown in Figure 13).13
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Figure 13. A quadrupole mass analyzer.

It is possible to utilize more than one mass analyzer for analysis, a technique known as
tandem mass spectrometry (MS/MS). One prevalent example is the triple quadrupole, wherein
two quadrupole mass analyzers sandwich a collision cell, which may or may not be a
quadrupole. So the name ‘triple quad’ can actually be a misnomer. The MS/MS instrument can
be used to select for a specific ion (the “parent ion”), fragment this ion, and then select or scan
for the various fragments (the “daughter ions”). Tuning the voltages of the collision cell allows
the triple quadrupole to reproducibly create fragments for a specific analyte. Not only is the
mass of the fragments identical each time but they are also produced in the same ratio each
time the parent ion enters the collision cell. Therefore, the triple quad generates what are
called “reference ion ratios”, meaning that the daughter ions seen are in a specific ratio to each
other and to the parent ion. This relationship allows analytes to be detected at high sensitivity
(low picomolar range), as they are identified not only by the LC retention time but also by the
reference ion ratio spectra. Tandem mass spectrometry provides a high level of specificity to
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the samples, which is advantageous when working with low concentrations of analytes in
complex mixtures.

Figure 14. Schematic of a triple quadrupole mass analyzer.

The time-of-flight (TOF) mass analyzer works in a different manner than the quadrupole.
In TOF, ions are accelerated through a potential, so they are starting with the same kinetic
energy. Ions are then sent down a drift tube, after which they arrive at the detector at different
times. If all ions have the same energy to start, then ions of different mass will have different
velocities by v=(2zeV/m)1/2 and therefore arrive at the detector at different times. The flight
tube has a known length, therefore the arrival time can be used by the instrument to calculate
the mass: t=(L2m/wzeV)1/2. TOF based mass spectrometers are often used with pulsed
ionization techniques (as is the case with the laser employed in MALDI-TOF) because the start
time and position must be known.13

20

The instrument used for MS imaging studies presented herein is a TOF/TOF instrument,
again employing tandem mass spectrometry to increase the specificity by which the instrument
can detect analytes within complex biological matricies. The instrument has two detection
modes, linear mode and reflectron mode. This instrument has two detectors available
regardless of the mode chosen. In linear mode, analytes are sent through the flight tube to the
detector without any fragmentation. This mode is typically used for very large biomolecules,
which have larger masses that are able to be resolved by one pass through the flight tube. In
reflectron mode, the ions are reflected to travel a longer path, which changes the ion arrival
time and therefore enhances the resolution. This is important for smaller analytes because it is
more challenging for the instrument to distinguish between small masses with very similar
arrival times.13

Figure 15. General schematic of a TOF mass analyzer. 23

The MALDI-TOF instrument employed for imaging experiments has a 2 kHz solid state
UV laser for acquisition at a wavelength of 355 nm. The diameter of the laser beam is
adjustable from 10 to 200 micrometers. Axial spatial distribution focusing (ASDF) is a
technology designed to address issues with the curved field reflectron, where mass resolution
21

can decrease as the instrument changes from MS to MS/MS mode.24 This mass resolution drop
is produced by the increased spatial distribution of the ions as they leave the sample surface.
ASDF aims to refocus this spatial distribution to keep the mass resolution independent of the
laser power. The mass resolution should also be independent of sample thickness and
topography. In the curved field reflectron, ions leave the MALDI source and are introduced into
the TOF analyzer with 20 kV of kinetic energy. The ions maintain this energy as they enter the
collision cell. The instrument employs high energy collision induced dissociation (CID), to
generate fragments for TOF/TOF analyses. The ASDF technology is just before the reflectron
and acts as a focusing lens for the fragment ions. The Shimadzu 7090 is designed to allow for
mass resolution up to 10,000. Ions which are chosen to be fragmented are allowed through an
ion gate combined with a collision gas which bombards the analytes and generates fragments.
The fragments are then detected by passing through the flight tube completing the TOF/TOF
analysis.
Tandem mass spectrometry is important to achieve high specificity. Thus, tandem mass
spectrometry provides low limits of detection (for example, 1 pg/mL sensitivity on the triple
quadrupole instrument). This low detection limit is possible due to reference ions that are
created and optimized for each analyte. Because LC-MS/MS analysis is specific to the fragments
generated, analytes do not need to be baseline resolved chromatographically. When working
with complex biological samples that are difficult to purify, the ability to select masses for
fragmentation and use those fragments to identify analytes is important.
3.2.3. The Detection System
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After ions have been separated by the mass analyzer, they are detected, typically by an
electron multiplier as illustrated in Figure 16. The electron multiplier tube contains a conversion
dynode, with a concave piece of metal angle that can angle the ion beam. The off-axis
orientation greatly reduces the noise by limiting the probability that a neutral molecule will
strike the conversion dynode. A high voltage is used to increase the conversion efficiency and
thus increase the signal (Figure 17). There is also typically a shield to protect the vacuum
manifold from the electric field produced by the conversion dynode.21

Figure 16. Ion detection system.21
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Figure 17. Amplification created when the ion beam is focused onto the conversion dynode, which emits
electrons in direct proportion to the number of ions bombarding the dynode. These electrons are
accelerated and focused onto another dynode, thereby creating a cascading effect from dynode to
dynode.25

1.4

Conclusions
In summary, the Arnold research group is interested in compounds that bind to the GABAA

receptor. This work illustrates the method development for several assays to characterize druglike properties of lead molecules. Several different mass spectrometers were implemented to
make these assays possible. The analytical accuracy of mass spectrometry is important and is
therefore utilized frequently in the drug discovery arena. The work presented in the subsequent
chapters shows how such a powerful technology can be employed to create information.
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CHAPTER 2. Liver Microsome Stability Assay
2.1

Introduction
In-vitro assays used for the evaluation of ADMET (absorption, distribution, metabolism,

excretion, and toxicity) properties are an essential part of drug discovery programs. In-vitro
studies are generally performed to individually study these compound properties. Assays of this
nature are extensively performed early-on to assess drug-like properties of lead molecules,
ideally in a high-throughput and inexpensive fashion. It is important to quickly gain information
regarding these drug-like properties when investigating a lead compound. These types of
studies inform medicinal chemists if a drug candidate might have desirable therapeutic effects
in vivo. With regard to metabolism within the ADMET field, optimum drug performance is
determined largely by xenobiotic liver metabolism, because drugs taken orally are absorbed
from the gastrointestinal tract and must pass through the liver in order to reach the circulatory
system. Once in the circulatory system, the drug can be transported to its target organ to elicit
a therapeutic response. However, it is rare for 100% of a dosed drug to reach the disease target
location. A fraction of the drug is lost by xenobiotic metabolism and excretion, which is referred
to as first-pass metabolism. A flow chart of how a xenobiotic is processed is illustrated in Figure
18. In vitro metabolic assays can be predictive tools for first-pass metabolism, as these

predictions are based on the metabolism of a compound in a known enzyme system. For
example, enzymes known to exist in the liver and in other locations in the body are cytochrome
P450 enzymes. Approximately 60% of all marketed drugs are cleared from the body by hepatic
cytochrome P450 metabolism.26 Although both phase I and phase II metabolic processes are
important for the metabolic processing of both exogenous and endogenous compounds,
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typically the interactions seen in phase I metabolism are initially considered for in vitro
metabolic studies. However, the study of metabolites generated by glucuronosyltransferase
enzymes are commonly seen as well, and these UGT enzymes are also present in liver
microsomes.27

Figure 18. The two phases of drug metabolism and how they generate resulting metabolites.1

The imidazobenzodiazepines investigated in this work are expected to undergo hepatic
metabolism and generate metabolites similar to those frequently seen for benzodiazepine drug
compounds, including hydroxylation products and benzophenone products. Figure 19 shows
the core benzodiazepine ring featuring a pendant phenyl ring, which is a functionality seen in
several of the lead compounds in this work. There are several prominent metabolic
transformations that are known to occur in the liver, such as oxygenation, reduction, and
hydrolysis, which are all dependent on the structure of the initial compound.
26

Figure 19. Illustration of benzodiazepine metabolism.28

In order to test the metabolic stability of drug compounds in vitro, an inexpensive assay
which can be conducted in a high throughput manner is required to efficiently screen as many
analogs as possible. Therefore, a “mix-and-go” assay featuring commercially available reagents
was optimized to meet this research need. Liver microsomes were chosen to provide the
enzyme system necessary to degrade drug candidates and generate metabolites in vitro. Liver
microsomes are subcellular fractions of liver cells, which are commercially available and have a
reasonable cost and shelf life. Microsomes have been shown to contain drug metabolizing
enzymes of interest such as the aforementioned cytochrome P450 enzymes (e.g. the
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monooxygenase CYP3A4) which play a significant role in metabolizing drug compounds in the
liver. Figure 20 shows the simple process of isolating microsomes from fresh liver tissue.
Typically, this tissue is purchased from organ procurement sources when deemed unsuitable
for human transplantation. The microsomes are the final product of the isolation scheme
shown below, however assays can also be conducted using the cytosol, as well as the S9
fraction (which is the cytosol and microsomes together).

Figure 20. Isolation of microsomes from liver tissue, typically acquired through organ procurement
organizations. Image: BD Biosciences

Due to the fact that these enzymes are known to play such a large role in the Phase I
metabolism in the liver, within the context of pre-clinical drug development this is one of the
first studies performed and published when investigating new drug compounds. Compounds
that do not display good metabolic stability may potentially be discounted from the list of lead
options, which is typically a lengthy list of compounds created by medicinal chemists. Generally,
unless a compound is a pro-drug, quickly cleared compounds are considered to be unfavorable.
28

In-vitro metabolic assays can also be used to investigate reactive metabolites, drug-drug
interactions, phenotyping, and de novo metabolite identification. Predictions can be made
regarding how drugs will be metabolized in the liver based on known enzymatic
transformations and previously published compounds with similar functionalities. Ultimately,
these predictions need to be verified and this type of in-vitro assay can be used to accomplish
that goal early-on in the drug development process. With regard to processing a xenobiotic, the
body’s metabolism is usually attempting to clear any xenobiotics. Often metabolic enzymes will
make compounds more polar to aid in excretion. Therefore, liver microsome assays performed
in vitro can also be used to enzymatically synthesize and identify metabolites that would be
excreted as well. It is very difficult to replicate an excretion system in vitro, therefore the liver
microsome assay is currently the best option for seeking to gain excretion info ex vivo.
Cytochrome P450 enzymes are heme-protein molecules. The heme group
(protoporphyrin IX) contains coordinated iron. It has been proposed that the substrate binds to
the active site followed by a reduction of the iron III of cytochrome P450 to the iron II state, by
a one electron transfer catalyzed by P450 reductase. Subsequently, molecular oxygen binds to
the iron II and is converted to an activated oxygen species.29 This system can be non-specific
and will oxidize a variety of substrates. Non-selective enzymes such as CYP3A4 metabolize a
large number of drugs including our current analytes of interest, imidazobenzodiazepines.
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Figure 21. Crystal structure of the midazolam-bound CYP3A4.30

In addition to identifying potential metabolites utilizing CYP450 enzymes, several numeric
parameters can be estimated from the in-vitro degradation of compounds by liver microsomes.
The assay presented herein estimates the rate of metabolism based on the free intrinsic
clearance, which is a description of metabolism due to enzyme activity alone (other factors
such as blood flow through the liver or drug binding percentages are not accounted for in the
calculation of intrinsic clearance).31 The values calculated for the clearance are based on the
Michaelis-Menten kinetic model in biochemistry, which is outlined in Equation 2. Under linear
conditions, as is the case with the liver microsome assay, the concentration at the enzyme site
is 10% or less of the Km, and equation 2 is reduced to form Equation 3.
Equation 2.

Rate of metabolism = Vmax*CE / Km + CE

Equation 3.

Rate of metabolism = Vmax*CE / Km
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The rate of metabolism is equal to the product of the intrinsic clearance and the
concentration of drug, and is expressed as μL/min/mg microsomal protein. The analogy
extended to an in vivo situation would be the volume of blood that is cleared of a drug per unit
time. Based on the same kinetic model, the metabolic half-life of the drug can also be
calculated (the time taken for the concentration of a drug to be eliminated to half of its original
value). This procedure has been optimized using both human and mouse liver microsomes to
identify any metabolic differences between species, as most pre-clinical assays are conducted in
mice. Drugs can behave differently in certain animal species, therefore it is necessary to
conduct this assay with both human and mouse liver microsomes to illustrate the metabolic
behavior in animal and human.
2.2

Materials & Methods
Four µL of 1 mM test compound (XHE-III-74 ethyl ester or XHE-III-74-Acid at a final

concentration of 10 µM) in DMSO were preincubated at 37°C for 5 minutes on a digital heating
shaking dry bath (Fischer scientific, Pittsburgh, PA) in a mixture containing 282 µL of water, 80
µL of phosphate buffer (0.5 M, pH 7.4) 20 µL of NADPH Regenerating System Solution A (BD
Bioscience, San Jose, CA) and 4 µL of NADPH Regenerating System Solution B (BD Bioscience,
San Jose, CA) in a total volume of 391.2 µL. Following preincubation, the reaction was initiated
by addition of 8.8 µL of either human liver microsomes (BD Gentest, San Jose, CA), or mouse
liver microsomes (Life technologies, Rockford, IL at a protein concentration of 0.5 mg/mL.
Aliquots of 50 µL were taken at time intervals of 0 (without microsomes), 10, 20, 30, 40, 50 and
60 minutes. Each aliquot was added to 100 µL of cold acetonitrile solution containing 1 µM of
verapamil HCL as internal standard. This was followed by sonication for 10 seconds and
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centrifugation at 10,000 rpm for 5 minutes. 100 µL of the supernatant was transferred into
Spin-X HPLC filter tubes (Corning Incorporated, NY) and centrifuged at 13,000 rpm for 5
minutes. The filtrate was diluted 100 fold and subsequently analyzed by LC-MS/MS with
Shimadzu LCMS 8040, (Shimadzu Scientific Instruments, Columbia, MD). The ratio of the peak
areas of the internal standard and test compound was calculated for every time point and the
natural log of the ratio were plotted against time to determine the linear slope (k). The
metabolic rate (k*C0/C), half-life (0.693/k), volume of distribution (Vd = volume of the assay (µL)
divided by the protein of the incubation in mg (2000 µL/mg in our assay)), and intrinsic
clearance (Vd*ln2/t1/2) were calculated, where C0 is the initial concentration of test compound,
C is the concentration of microsomal protein. All time points were repeated in triplicate. Human
and mouse liver microsomes were purchased as a 50 donor pool to ensure sufficient diversity
for reproducible assay results. NADPH is a necessary co-factors for enzymatic activity, therefore
when this fuel for the enzymes has been used up in its entirety, the enzymes can no longer
metabolize xenobiotics and the conversion will stop. HyClone phosphate buffered saline was
purchased from Fisher Scientific (Waltham, MA). The initial development of this assay was
performed on a Thermo HPLC with a PDA detector. Further optimization and metabolite
identification was performed on a Shimadzu 8040 triple quadrupole UHPLC-MS/MS system as it
became available. Optima LC/MS grade methanol, acetonitrile, formic acid and water were
purchased from Fisher Scientific. Separation was performed on a Restek C18 column (25 mm x
2.1 mm, 3 µm particle size). Uracil was purchased at Sigma Aldrich (Milwaukee, WI) and used to
measure the instrument void time. Test compounds were synthesized as published previously32
and received as pure powder, which was weighed and dissolved in DMSO to create original
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stock solutions at [10mM]. Stock solutions were diluted to a working concentration of 1 mM,
also in DMSO, as described above. Microsomes were stored at -80°C prior to use and thawed
over wet ice. All solutions purchased (NADPH and microsomes) were aliquot into smaller
volumes to minimize the number of freeze/thaw cycles. Solutions A contains NADP+ and
solution B contain glucose-6-phosphate dehydrogenase to create NADPH when combined. The
initial assay solutions consisted of a mixture of 200 µL total, 10 µL of solution A, 2 µL of solution
B, 2 µL of 1 mM stock in DMSO were added to 181 µL of PBS. However this volume was
increased over time to allow for additional replicates. This mixture was pre-incubated for 5
minutes to reach physiological temperature, followed by the addition of 5 µL microsomes (20
mg/ml protein concentration). Initially, 30 µL of the microsomal assay mixture was taken out at
time points 0, 5, 10, 15, 30 and 60 minutes and immediately added to 1 equivalent volume of
cold acetonitrile containing a pre-chosen internal standard. However, these time points were
altered to be every ten minutes, to generate more consistent plots. The acetonitrile used to
precipitate the protein was upgraded from standard reagent grade to LC-MS grade when the
methods were to be run on the LC-MS/MS instrument. In the original development of this
assay, the quenched mixture was spun down at 10,000 rpm for 5 minutes, the supernatant
withdrawn from atop the protein pellet, transferred to a 384 well plate and placed directly onto
the HPLC-UV instrument. However, additional filtration steps were later added prior to LC-MS
analysis, using 0.22 μm nylon spin filter vials. Although all particulates and large proteins should
be removed from the acetonitrile by precipitation and centrifugation, it was determined that
additional filtration was necessary to generate clean, consistent data on the LC-MS 8040. This
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procedure was developed in duplicate and increased to triplicate repeats for more reliable
results and lower standard deviation values.
Initial method development and analyses were performed on a Thermo LTQ HPLC-UV
instrument. However, shortly after this assay was developed the method was transferred to the
triple quadrupole UHPLC-MS/MS instrument (Shimadzu 8040). The initial analysis conditions
performed on the now decommissioned HPLC-UV system were under isocratic conditions, 30%
acetonitrile and 70% water. The flow rate was 150 μL/min, with a column oven temperature of
50°C and a pressure of 75 bar. This instrumental method was problematic due to a consistent
yet sloping baseline, as pictured in the chromatogram below. Although the peak shape is
sufficiently symmetrical and the signal to noise ratio is calculated as infinite, it is not ideal to
have such a baseline. HPLC-UV also shows a large solvent front, which is not seen on the LCMS/MS instrument, as MS/MS methods are specific to the masses of interest. Although the
HPLC-UV chromatogram shows sufficient baseline separation for each peak, as well as sufficient
signal to noise, the peak shape does illustrate some tailing, and the proximity of the first peak
to the solvent front is somewhat concerning. Typically this issue can be remedied with
modifications to the mobile phase conditions, such as switching from acetonitrile to methanol,
decreasing the flow rate, or increasing the water content in the mobile phase. However, these
typical troubleshooting strategies were not sufficient for the analysis initially because the C18
column was well past retirement. Column care is exceptionally important for the lifetime of the
column in liquid chromatography, if the column is stored uncapped or not handled carefully, it
will dry out the stationary phase and deteriorate the column’s ability to sufficiently retain
analytes.
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Analyte k = 0.9038
Internal Standard k = 3.9808
α = 4.42
Rs = 4.71

Figure 22. HPLC-UV analysis of drug compound degradation by human liver microsomes. The peaks
shown are the solvent front (tr: 0.52 min), the analyte (tr: 0.99 min), and the internal standard (tr: 2.59
min). RT is retention time, AA is the area of the peak, AH is the peak height, and SN is the signal to noise
ratio.

Upon implementation of the triple quadrupole instrument, a new C18 column was
purchased for microsomal assay analysis. Analytes were optimized individually by testing
collision energies from -15 to -40 V in positive mode, tested in increments of 5. Proposed
fragmentation patterns for analytes are listed in Appendix A. Masses and voltages used for
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reference ion ratios are listed in Appendix B. All fragmentation patterns were optimized with
pure compounds dissolved from powder into mobile phase.

Figure 23. Chromatogram from the triple quadrupole LC-MS 8040. Each peak represents the total ion
chromatogram followed by each ion in the reference ion ratio (underlying peaks). For example, the peak
at RT 4.4 minutes is for verapamil. The largest peak in blue is a sum of all the ions for that compound.
The second largest peak in light blue is for most abundant of the reference ions, followed by smaller
peaks in red and black for the less abundant reference ions for verapamil.

2.3

Results and Discussion
Peak areas were integrated by LabSolutions software and the analyte area was divided

by the area of the internal standard, to create a ratio. This ratio was converted to a percentage
by taking the zero time point as 100% and scaling the ratio values to that assumed zero. Then,
to compute pharmacokinetic parameters, the natural log of the percentage was plotted and fit
with a linear regression (as illustrated in Figure 24). The metabolic half-life was calculated by
taking the natural log of 2 divided by the slope of the regression line. The volume of distribution
for our assay was 2000 μL/mg. That volume of distribution was the multiplied by the ln(2) and
divided by the previously calculated metabolic half-life to yield the internal clearance. The
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metabolic rate is determined by the slope of the regression line multiplied by the concentration
of compound (10000 nM) and divided by the concentration of protein (500 mg/l).

Slope of regression line = 0.005904
Half-life: ln(2)/slope
0.693/0.0059 = 117.5 minutes
Clearance: Vd*ln(2)/half-life
2000μL*0.693/117.5 = 11.8
μL/min/mg protein

Metabolic Rate: Slope *
[compound]/[protein]
0.0059*(10 000 nM/l)/(500 mg/L) =
0.118 nmol/min/mg
Figure 24. Example of calculations performed for liver microsome assays.

Figure 25. Percentage plot of human liver microsome results for α5β3γ2 and α4β3γ2 GABAAR selective

ligands.
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Table 1. Metabolic parameters for seven imidazobenzodiazepine compounds.
Compound
Metabolic
Half Life,
minutes
Intrinsic
Clearance,
uL/min/mg
Metabolic
rate,
nM/min/mg

HZ-166

MP-II-069

MP-II-068

Xhe-III-74

Xhe-III-74
EE

MRS-I-36

CMD-45

117.46

116.20

200.58

663.79

334.94

2252.93

4129.92

11.8

11.9

6.9

2.1

4.1

0.6

0.3

0.118

0.119

0.069

0.021

0.041

0.006

0.003

Figure 26. Structures correlating with the results for several imidazobenzodiazepine compounds.

Figure 27. α4β3γ2 selective ligands, natural log plot.
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Figure 28 α5β3γ2 selective ligands, natural log plot.

The results for this assay show a distinct difference in metabolic stability between the
α4β3γ2 selective GABAAR ligands and the α5β3γ2 selective GABAAR ligands alpha 5 receptor
ligands. The compounds that are selective for the alpha 4 receptor have an extra ring attached
directly to the core structure, in a rigid position that will prevent metabolism at the 4 position
of the seven membered ring. The alpha 5 receptor ligands, however, do not have a ring in this
position, they have a pendant phenyl ring that is designed to fit into the binding pocket (as
shown in the structures in Figure 26). These structural differences lead to subtype selectivity,
but also have an impact on the in vitro stability of these compounds.
This assay can also be used to identify metabolites that are generated by CYP450
enzymes. Although the quantitation is done in MRM mode, which identifies a specific mass and
subsequently fragments of that mass, the assay samples can also be scanned over a mass range
in an attempt to identify metabolites. General scans can be performed on a quadrupole
instrument, but for more detailed analysis and formula prediction, the high resolution IT-TOF
39

presents the opportunity to research in depth metabolomics. One such example of a newly
discovered metabolite generated through the microsome assay is presented in Figure 29. The
hydroxylation product for the MP II 069 compound was identified in scan mode on the LC-MS
8040 at the 60 minute time point. As this time point, which is at the end of the assay, enzymatic
transformations have occurred and therefore metabolites are present in the solution.

Figure 29 Scheme of the metabolism of MP II 069 by hydroxylation.

Metabolomics is in and of itself a vast research area within the field of drug discovery.
With the resources available to the MIDD, this is a promising future direction that the medicinal
chemists at UWM will be able to pursue to further understand the pharmacological promise of
lead compounds.
This assay has been successfully developed to investigate the metabolic stability of
various lead compounds under in vitro conditions. This procedure has been implemented to
study not only imidobenzodiazepines synthesized by the Cook group, but other compound
types as well for a variety of projects. Prior to the development of this assay, medicinal
chemists at UWM would be required to utilize external contract research organizations for
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metabolic stability studies. One such example is the compound HZ-166, which was investigated
by a contract research organization as published previously.33 The assay presented above shows
good correlation with the CRO results (indicating this compound to have 66% of the parent
remaining after one hour), further illustrating the effectiveness of the method presented.
In conclusion, this assay is a commonly used screening tool that has been implemented
in the MIDD to screen over 100 compounds to date. This assay provides a sufficiently highthroughput approach to the assessment of metabolic stability.
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CHAPTER 3. Primary Human Hepatocyte Assay
3.1

Introduction
Assays which employ human liver microsomes to illustrate analyte degradation give

medicinal chemists valuable information regarding in-vitro stability of lead compounds because
they contain important drug-metabolizing enzymes such as CYP450 enzymes. However,
microsomes do not contain the full complement of enzymes that a drug will encounter during
metabolism in the liver.26 Although the liver microsome assay is rapid, inexpensive, and
therefore useful in high-throughput screening, it can be necessary to carry out additional
metabolic stability assays using cell culture. To gain insight into the metabolism a drug will
encounter in the liver, it is obvious to use a liver cells for in-vitro screening. These so called
hepatocytes can be harvested directly from liver tissue and can be cultured for a limited period
of time. An alternative is the use of immortalized or carcinogenic liver cells that can be
propagated unlimited in cell culture. Freshly isolated liver cells are called primary human
hepatocytes, which have become the “gold standard” for looking at hepatic clearance as well as
identifying drug metabolites in-vitro. It is important to mention that liver microsome contain
less enzymes than the hepatocytes they are derived from. One example are transport proteins
that may play a role in the performance of a drug compound.34 Typically, primary human
hepatocytes are isolated from livers deemed unsuitable for transplantation and are relative
expensive. They can be plated and cultured, however the maximum time that they will typically
live is a few days. Therefore, the use of primary human hepatocytes, while it is the best case
scenario for gaining insight into the hepatic clearance of a drug in Phase I metabolism, is far too
expensive to employ for a high throughput preclinical assays. For that reason, it is typical
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practice to use liver microsomes to screen a large number of compounds, and only the most
promising lead compounds are investigated with a hepatocyte based metabolism assay.
In addition to the high cost and limited life span of freshly isolated primary human
hepatocytes, they are also phenotypically unstable and exhibit large variations between donors
when mixed.35 Commercially available human liver microsomes are typically pooled from 50
donors in order to eliminate large variations. This is not an option for primary hepatocytes.
Alternatively, utilizing a hepatoma cell line (derived from cancer cells) has become a more cost
effective research option. Several cell lines currently exist as options, and are employed for this
purpose. These include HepG2, Hep3B, Huh7, HBG, HepRG and PLC/PRFs.35 In general, cell lines
derived from cancer cells easy proliferate. HepG2 cells have lost some functionality since their
initial establishment as a hepatoma cell line, however, drug-metabolizing potentials can still be
characterized for each cell line and are shown to be of use in drug discovery programs.
Typically, suppliers of these cell lines will characterize pertinent proteins (such as cytochromes)
expressed by these cells. With regard to xenobiotic metabolism, these cells generate some of
the metabolites that would be formed in vivo, although the quantitative amounts are different.
This makes sense because the human body has many different organs responsible for
metabolism and therefore the number and quantity of enzymes available to process a drug are
clearly very different from cell culture. The quantity of parent compound and metabolites
varies based on the chemical composition, amount of compound, number of cells, media and
temperature. Both Phase I and Phase II metabolizing enzymes can be transcriptionally induced
in cell culture and will change with the culture conditions. Primary cells from different donors
inherently have very high batch variability but represent the different metabolism by patients
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taking these drugs eventually. However, this variability is a disadvantage when it comes to
reproducible quantification of generated metabolites and parent drug degradation. Hepatoma
cells don’t change their genetic makeup in culture thus metabolic stability assay results are
more uniform. Therefore, HepG2 are a useful substitute for assay development and have been
employed in the studies listed herein.
3.2

Materials & Methods
HepG2 cells were purchased from ATCC (Manassas, VA) and were stored in liquid

nitrogen prior to use. Cells were quickly thawed at room temperature and added to 20 mL of
Minimum Essential Medium (Hyclone, #SH3024301) media in a culture flask to which nonessential amino acids (Hyclone, #SH30238.01), 5 x 106 units of penicillin and streptomycin
(Hyclone, #SV30010) and 10% of heat inactivated fetal bovine serum (Gibco, #10082147) were
added. The cells were grown for 3 days at 37° C with 5% CO2, trypsinized with 0.25% Trypsin
(Hyclone, #SH3004201) for 5 minutes to detach from the cell culture flask and were then added
to 20 mL fresh MEM media. Cells were spun down in conical tubes at 1000 rpm for 3 minutes,
resuspended in a smaller volume of MEM media and counted with a hemocytometer at 4.2
million cells per mL. Cells were diluted 2x with additional MEM media and aliquots of 100 μL
were dispensed into wells of a sterile 96 well plate (Nunc #12-566-71). 0.5 μL of compound (2
mM in DMSO) at different concentrations was dispensed into each well of the 96 well plate for
a final incubation concentration of 10 uM (0.5% DMSO). The plate was incubated for 24 hours
at 37° C with 5% CO2. 65 µL of media was aspirated and combined with 130 µL of cold
acetonitrile solution containing 1 µM of verapamil HCL as internal standard. This was followed
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by sonication for 10 seconds and centrifugation at 10,000 rpm for 5 minutes. 100 µL of the
supernatant was transferred into Spin-X HPLC filter tubes (Corning Incorporated, NY) and
centrifuged at 13,000 rpm for 5 minutes. The filtrate was diluted 100 fold and subsequently
analyzed by LC-MS/MS with Shimadzu LCMS 8040, (Shimadzu Scientific Instruments, Columbia,
MD). The ratio of the peak areas of the internal standard and test compound was calculated for
every time point and the natural log of the ratio were plotted against time to determine the
linear slope (k). The half-life (0.693/k) was calculated.
3.3

Results & Discussion
Several compounds were screened using the HepG2 cell based assay. Initially, the first

compound chosen was MP III 024 (Figure 30), which was incubated for 90 minutes with HepG2
cells. Unlike for the liver microsome assay, no notable change in the concentration of MP III 24
was observed for a period of 90 minutes. Therefore, after this initial run it was decided to
extend the timeline of this assay to two hours (Figure 31).

Figure 30 Structures for α5β3γ2 GABAAR selective ligands.
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Figure 31. Results for α5β3γ2 GABAAR selective ligands in HepG2 cell stability assay, presented as percent
compound remaining over the course of two hours. The left plot shows the linear regression from 65 to
100%, the right plot shows the percent scale from zero to 100%.

We observed that all three compounds were relative stable in the presence of HepG2
cells. In comparison the half-lives in the presence of liver microsomes were 167 minutes SH053, 209 minutes MP-III-024 and 158 minutes Hz-166. The calculated stability parameters for
HepG2 cells are presented in Table 2.
Table 2. Stability parameters for α5β3γ2 GABAAR selective ligands.

Compound

Half Life, min

R square

Sy.x

MP-III-024
SH 053
HZ 166

432.1366
647.1962
423.9432

0.9069
0.5197
0.7924

0.01862
0.04819
0.04225

Deviation from
linearity
Not significant
Not significant
Not significant

The half-lives of α5β3γ2 GABAAR selective ligands were lower than those determined with the
liver microsome stability assay. It is generally known that microsome stability assays actually
overestimate the internal clearance for a compound, as illustrated in Figure 32. The clearance
of these FDA approved GABAAR ligands is significantly faster in microsomes that in the presence
of fresh hepatocytes. The data seen in this work is thus consistent with the trend published in
the literature.
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Figure 32. Comparison of CL values for five benzodiazepine compounds as estimated in human liver
microsomes, human cryopreserved hepatocytes, and fresh human hepatocytes.36

The assay described herein involves a living cell system, therefore many factors
contribute to the repeatability of this assay. HepG2 cells are an adhesion cell line thus they
grow on the flask bottom. A substance called matrigel is often used to assist in adhering cells to
plastic surfaces during cell culture. This assay was tested both with and without matrigel.
However, it was determined that the addition of this material to the assay plate did not have
any noticeable effect the results of this assay.
During the time this assay was being developed, the Cook group synthesized many
deuterated analogs in an effort to exploit the kinetic isotope effect for metabolic stability. A
carbon-deuterium bond is more difficult to break than is a carbon-hydrogen bond, thus it is
expected that the deuterated analogs would display better stability in both the human liver
microsome assay as well as the hepatocyte assay. The kinetic isotope effect is a commonly
studied phenomenon in the field of drug development and was therefore a logical strategy for
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the medicinal chemists synthesizing compounds for this work to increase metabolic stability.
The compounds investigated were α4β3γ2 GABAAR selective ligands (Figure 33).

Figure 33. Structures of α4β3γ2 GABAAR selective ligands .

Also these compounds were investigated with the developed HepG2 cell stability assay and the
results are summarized in Figure 34.

Figure 34. Results for four α4β3γ2 GABAAR selective ligands in HepG2 cells.
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We observed that the four compounds displayed different stabilities in the presence of HepG2
cells. In comparison the percentage left after 60 minutes in the presence of liver microsomes
was 59% XHE-III-74, 65% XHE-III-74 OCD3, 77% XHE-III-74 ethyl ester, and 99% XHE-III-74 ethyl
ester OCD3. The calculated stability parameters are presented in Table 3.
Table 3. Stability parameters for α4β3γ2 GABAAR selective ligands.
Compound

Half Life, min

R square

Sy.x

Xhe III 74

184.2007
255.3969
293.4577
2690.7887

0.8708
0.4782
0.7313
0.0287

0.0627
0.1233
0.0619
0.0662

Xhe III 74 OCD3
Xhe III 74 EE
Xhe III 74 EE OCD3

Deviation from
linearity
Not significant
Not significant
Not significant
Not significant

Figure 34 showed that little variation in hepatocyte stability between the OCH3 and OCD3

analogs for the original Xhe III 74. However, for the Xhe III 74 Ethyl Ester compound, the
substitution of the OCH3 to the OCD3 did appear to increase the metabolic stability in the cellbased assay based upon this plot. However, upon closer evaluation at the 95% confidence
interval, the data can be assessed for a slope that deviates significantly from zero. Due to the
larger error bars for the Xhe III 74 OCD3 compound (shown in blue) this statistical test does
show that for both the OCD3 analogs, the slope does not deviate significantly from zero,
whereas the original lead compounds without deuterium do significantly deviate from zero.
These preliminary assay results do indicate that the substitution from OCH3 to OCD3 does in fact
increase the metabolic stability of the compound.
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Figure 35. Xhe III 74 and its deuterated analog shown with the 95% confidence interval.

Figure 36. Xhe III 74 Ethyl Ester and its deuterated analog shown with the 95% confidence interval.

The linear regression results for the α4β3γ2 GABAAR selective ligands presented in Figure 35 and
in Figure 36 as shown for the deuterated and non-deuterated version of each compound, with
the error bars bracketed for the slope of the linear regression at the 95% confidence interval
(shown in dashed lines).
The intrinsic clearance estimated by in vitro metabolic assays such as the liver
microsome stability assay and the hepatocyte cell-based assay provide useful information
regarding both Phase I and Phase II metabolism of drugs in the liver. We have successfully
established a cell-based metabolic assay for the assessment of compound stability in vitro. The
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assay can be carried out with the inexpensive HepG2 cells. In the future, this assay can be
adapted with slight modifications to test compounds in fresh or cryopreserved human
hepatocytes.
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CHAPTER 4. In vitro Brain Metabolism Assay
4.1

Introduction
Stereochemistry is an important consideration in drug development. Stereoisomers are

compounds with the same molecular formula and bonds, but different three dimensional
structures. Stereoisomers are divided into subcategories of enantiomers (mirror-images) and
diastereoisomers (non-mirror images).37 It is important to consider the spatial arrangement of
the atoms within a drug compound because the three-dimensional orientation of the functional
groups must fit into the three-dimensional binding pocket of the target receptor. Therefore, the
drug-like properties of a molecule can be greatly impacted by variations in stereochemistry.
Approximately 25% of drugs currently on the market are comprised of a mixture of
stereoisomers, however the biological activity may be predominantly or wholly induced by one
stereoisomer in the mixture. One simple example is ibuprofen, in which the R conformation is
inactive but the S isomer displays the therapeutic effect.1-2 This drug is sold as a racemic
mixture. While some components of a racemic mixture may display no effects, enantiomers can
also display different physicochemical properties resulting in adverse effects or toxicity. 37
Proteins are composed of amino acids, which are chiral molecules, thus differing stereoisomers
may interact differently with a particular protein. The classic example of the dangers of
stereoisomerism lies in the story of thalidomide.2 This compound was prescribed as an antinausea medication to pregnant women and the alleviation of the symptoms of nausea was a
result of the R enantiomer of this drug. However, the S enantiomer caused birth defects. For
this reason, this drug cannot be sold as a racemic mixture. Furthermore, even if this drug was
synthesized and marketed as a single enantiomer, the R enantiomer alone, the body actually

52

creates a racemic mixture. Thalidomide (Immunorin or Contergan) caused limb deformities in
many children in the 1960’s, as a result of restricted blood flow to developing limbs.38
Serendipitously, thalidomide is investigated as a potential anti-cancer drug, for types of tumors
that require an ample blood supply to grow.2, 39

Figure 37. The S and R isomers of Thalidomide, which are effective, and dangerous, respectively.

Herein, we describe the investigation of the S and R enantiomers of chiral
imidazobenzodiazepines that bind the GABAA receptor in the brain. As a pentameric receptor,
the GABAA receptor contains five subunits, typically two α, two β, and a fifth, often γ subunit.10
This assembly has multiple variations for each of these receptor subunits. GABAA receptors
contain α1, α2, α3 or α5 subunits together with a neighboring γ2 subunit, which is where
benzodiazepines act as positive allosteric modulators. However, less than 5% of all GABA A
receptors in the brain have α5 subunits however α5β3γ2 GABAARs are common in the spinal
cord.40 Therefore, this receptor has been targeted by the Cook group and other as a therapeutic
strategy for neuropathic pain.41 Through pharmacokinetic studies of a particular compounds of
interest, SH-053-2’F-R/S-CH3 was identified as lead compound and differences were seen in vivo
with regard to concentrations of its enantiomers in rat brain. To investigate the hypothesis that
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the enantiomers have different stability in the brain, an in vitro metabolic assay was developed
to investigate the differences between the R and S stereoisomers.

Figure 38. Structures of chiral α5β3γ2 selective GABAAR ligands and a proposed metabolite of both
isomers identified in vivo.

We have shown in previous assays such as the liver microsome assay and the
hepatocyte assay that the activity of cytochrome P450 enzymes plays a crucial role in Phase I
xenobiotic metabolism. Although it is well known that these enzymes are present in large
quantities in the liver, recently it has been demonstrated that many of these enzymes are also
present in the brain.42 Examples of CYP450s that have been identified in both tissues are
displayed in Figure 39.

Figure 39. Known cytochrome enzymes and their identified substrates.42
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Therefore, the brain metabolism assay aims to gain information regarding drug-metabolizing
enzymes in the brain and enable later comparison with the in vivo PK results.

4.2

Materials & Methods
Male Wistar rats (250-350 g.) were housed in pairs and kept on a 12h dark/light cycle

(lights on at 7:00 am) with food and water provided ad libitum. For testing, a single rat was
euthanized (asphyxiated via CO2 chamber) in accordance with IACUC, and decapitated with a
small animal guillotine. The brain was extracted and weighed by difference into a 15 mL conical
tube. One equivalent of pre-heated PBS (37°C) was added by mass and the mixture was
homogenized with a LabGen T2 homogenizer. Individual centrifuge vials (1.5 mL) were prepared
(100 μL PBS, 20 μL of a 100 μM stock solution of test compound, 80 μL brain homogenate) for
eight (0, 10, 30, 60, 120, 240, 480, 1440 min) time points and placed in an oscillating heat-block
(37°C, 300 rpm). At each time point, the reaction vial was quenched with double the volume of
cold acetonitrile (400 μL) containing a 10 μM internal standard (HZ-166) and placed on ice. The
vials were vortexed and centrifuged (10,000 rpm) for three minutes and the supernatant was
pipetted into a spin filter centrifuge tube (0.22 micron nylon) for filtration. Samples were
diluted 20x into Optima LC-MS grade methanol (Fisher Scientific) by pipetting 25 μL of
supernatant solution into 475 μL methanol in a glass autosampler vial. Samples were analyzed
using a Shimadzu LCMS-8040. Three independent experiments were performed (n = 4 for each
independent experiment).
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4.3

Results
The graphs shown in Figure 40were created by the Savic group following a

pharmacokinetic study of both the R and S isomers of the SH-053-2’F-R/S-CH3 compound in
Wistar rats.33 The concentrations found for both isomers in the brain were comparable,
however the concentrations seen for the S isomer in plasma were an order of magnitude below
that of the R isomer.

Figure 40. Pharmacokinetic profiles of the R and S isomers of the SH-053-2’F-R/S-CH3 compound.

The pharmacokinetic profiles displayed above show a discrepancy between the plasma
concentrations of SH-053-2'F-S-CH3 and SH-053-2'F-R-CH3. One hypothesis is that both SH-0532’F-R/S-CH3 undergo active transport into the brain thus even at a low blood concentration for
SH-053-2'F-S-CH3 a high brain concentrations can be reached. The clearance of SH-053-2'F-SCH3 is fast, which has been confirmed by human liver microsome stability assays that indicated
that the S enantiomer is degraded at a faster rate than the R enantiomer. In addition,
comparing the concentrations of both stereoisomers in the brain, we observed a faster
clearance of SH-053-2'F-S-CH3 than SH-053-2'F-R-CH3 in the brain.
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Thus, to investigate if transport or brain metabolism are the underlying processes a brain
metabolism assay is carried out. This ex vivo assay utilizes fresh brain homogenates and
compounds are incubated at 37°C. The compounds are quantified at different time points and
the results are summarized in Figure 411.

Figure 41. Results of the brain homogenate assay displayed as a percentage remaining as well as the
linear regression (and the 95% confidence interval).

SH053-2'F-R-CH3 compounds were incubated with rat brain homogenate and quantified
by LC-MS/MS. The results are presented as a percentage remaining over the course of 24 hours
(three independent assays with an N=4 replicates for each assay). The results of this assay are
fitted with a linear regression to calculate metabolic half life, as with the microsomal stability
and hepatocyte assays. Based on the linear regression the slope was used the calculated the
half-life and other pharmacokinetic parameters summarized in Table 44.

Table 4. Estimated metabolic parameters for the R and S isomers in brain tissue homogenates.
Compound

Half Life, min

Internal Clearance,
uL/min/mg

R square

Sy.x

SH-053-2'F R CH3

7369.2024
1607.8571

0.0188
0.0862

0.3426
0.8419

0.0570
0.0931

SH-053-2'F S CH3
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Deviation from
linearity
Not significant
Not significant

The results of the brain stability assay show that the S-isomer (50% remaining after 24 hours)
was degraded at a faster rate than the R-isomer (84%). The half-life of SH-053-2'F-R-CH3 in the
brain is 4.5 times longer than SH-053-2'F-S-CH3.

4.4

Discussion
In addition to the pharmacokinetic data presented above, the Savic group identified a

potential metabolite of mass 267.25 g/mol at a ratio of 10:1 when derived from the S isomer
(ratio of metabolite:parent), whereas the R isomer yielded the same metabolite at a ratio of
1:10. Although the data regarding this proposed metabolite is consistent with the idea that the
S isomer is more readily metabolized than is the R isomer, this metabolite was not seen in the
brain homogenates assay, and therefore cannot be quantified at this time.

These results show a clear trend in the difference between R and S isomers when
exposed to metabolic enzymes in the brain. The P value for the comparison of these slopes is
P<0.0001, meaning that if the overall slopes were identical, there would be less than a 0.01%
chance of randomly choosing data points with slopes as different as those presented above.
Therefore we can conclude that the differences seen between the slopes in this assay are
extremely significant. This brain metabolism assay is a relatively low-cost method with rapid
analysis times to view the degradation of drug compounds in fresh brain homogenates. If this
assay is to be continued in the future, one could investigate the viability of freezing brain
homogenates at -80°C for a quicker sample preparation setup, or isolating the drug
metabolizing enzymes within sub-cellular fractions as is done for the liver microsome stability
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assay. These future directions have not yet been tested, leaving room for additional in vitro
development with regard to brain metabolism of drug compounds.
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CHAPTER 5. Quantification of GABA with a novel HILIC based method
5.1

Introduction
Ion channels are transmembrane proteins that contain a central pore to establish and

control voltage potentials across cell membranes. They do this by controlling the active flow of
ions between the intracellular and extracellular environments. This family of proteins is
involved in a diverse array of physiological functions, therefore ion channels are popular
therapeutic targets in drug discovery today.43 The lead compounds for the drug development
projects outlined in this work are modulators of the GABAA receptor. This receptor is a ligandgated ion channel, where gamma amino butyric acid is the endogenous ligand, and binding of
this ligand controls the flow of chloride ions through the channel. Typically, the flow of chloride
ions through this receptor is governed by GABA. The binding of a GABAA receptor agonist (such
as a drug compound) to the receptor will modify the flow of chloride ions. This flow of ions can
be measured to test compound effects on the receptor, using ion channel screening assays (e.g.
ligand

binding,

patch

clamp,

fluorescence

and

luminescence

based

assays,

and

electrophysiology). These assays are conducted in vitro thus it is paramount to understand the
circumstances and conditions in the organism itself to recapitulate similar conditions in vitro. In
the case of GABA, it has been well documented that T cells in addition to neurons produce
endogenous GABA in vivo and in culture.44 Important for the biosynthesis of GABA is the
expression of glutamic acid decarboxylase, which catalyzes the decarboxylation of glutamate to
GABA, therefore producing the endogenous ligand. A cartoon of the existing components
within a T cell is shown in Figure 42.
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Figure 42. Cartoon image of the coexisting GABA, GABAA receptor, glutamic acid decarboxylase (GAD),
and the GABA transporter 1 (GAT).

Interleukin 2 (IL-2) is a protein that is known to play an important role in inflammation. 45
The lead compounds investigated in this work are seeking to treat diseases that result from
inflammation, for example airway inflammation is a main symptom of asthma. Neuropathic
pain is also closely tied to inflammation46 and is being investigated by MIDD researchers as a
therapeutic target for benzodiazepines. It is of interest to know if a drug molecule can decrease
inflammation therefore our research group employs an IL-2 ELISA assay to assess the protein
expression in cell culture. Similarly, a calcium detection assay is employed to look at the
aforementioned ion transport (as the GABAA receptor is an ion channel). The IL-2 ELISA assay is
performed using a leukemia T cell line (Jurkat cells) and like the calcium assay GABA in addition
to positive GABAAR modulators has an influence on the outcome of the assay. For this reason a
method was developed to quantify the amount of GABA present in cell culture media. The cell
culture media consists of among others of salts, amino acids, sugars and most importantly fetal
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bovine serum. An efficient LC-MS method was developed to inject a sample with minimal front
end preparation. However, GABA is a very small analyte with a limited hydrophobic character,
which presents analytical challenges in the aforementioned LC-MS methods, which employ
reversed phase separation by HPLC.
The assays mentioned previously produced samples that could be analyzed with
conventional reversed-phase material as stationary phases (for example, C18). These stationary
phases contain hydrophobic groups, thus the analytes must display adequate hydrophobicity in
order to interact with the stationary phase. For benzodiazepine-like GABAA receptor
modulators of interest in this work, the majority of the compounds are of sufficient
hydrophobic for this separation technique (as is typical for most drug compounds). However,
analytes that are very polar are not compatible with conventional reversed-phase analyses
because they cannot be retained on a reversed-phase analytical column. GABA for instance is
not retained on a reversed phase column, making quantitation by LC-MS a challenge. One
approach employed to quantify amino acids and other polar analytes include a front-end
derivatization technique prior to LC-MS analysis. However, these strategies complicate the
sample preparation, add extra cost for chemicals needed to create a derivative, and can result
in non-specific derivatization of other compounds within the complex biological matrix to be
analyzed. Therefore, when separation of more polar analytes is required, a different separation
strategy called hydrophilic interaction liquid chromatography, or HILIC, can be employed. The
advantage of this approach is the ability to maintain a simple sample preparation and direct
sample analysis. Herein, we show that GABA is retained and quantifiable by HILIC
chromatography.
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For HILIC chromatography, the silica stationary phase particles are coated with a functional
group designed to draw and retain water on the surface of the silica. One such example, which
is employed in these analyses, is cross-linked diol groups for polar selectivity. This water layer
facilitates the transfer of polar compounds from the mobile phase to the stationary phase,
increasing the retention factor, whereas on a reversed phase column polar analytes would
elute around the void time, making separations difficult. A representation of the stationary
phase coated with an adsorbed water layer is shown in Figure 43. The water layer shifts the
retention mechanism from being primarily hydrophobic interactions (as in a C18 column) or π-π
interactions (as in a biphenyl column) to partitioning, rather, between the adsorbed water layer
and the analyte in mobile phase. The mobile phase for HILIC separations is typically very similar
to what is seen in reversed phase separations, largely organic with a small percentage of water
(3-15%) to hydrate the stationary phase and adequately dissolve the polar analytes.
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Figure 43. Cartoon representation of the polar stationary phase, the adsorbed water layer, and the
partitioning mechanism of retention seen in HILIC separations (Image: Waters).

5.2

Materials & Methods
Jurkat cells were maintained in suspension in RPMI 1640 medium with L-glutamine (Thermo

Fisher Scientific Inc., Rockford, IL) supplemented with 10% (v/v) fetal bovine serum. The cells
were maintained in 5% CO2, 95% humidified air at 37 °C at an approximate density of 106
cells/mL. Typically for the calcium assay, the Fluo-4 NW calcium assay kit (Life Technologies,
Rockford, IL) is used for intracellular calcium measurements. Jurkat cells are collected, pelleted,
and resuspended in Fluo-4 NW assay buffer at a final concentration of 5 × 106 cells/mL and
dispensed into a 384 well plate. The plate is then analyzed as described previously. One
microliter of test compound in DMSO or GABA in water is added to each well and incubated, to
illustrate a dose response for either the compound, the endogenous ligand, or both.
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Separation was performed on a Phenomenex Luna HILIC column (50 x 2.1 mm, 3 μm). The
mobile phase was isocratic at 85% acetonitrile and 15% water. The mobile phase contained 5
mM ammonium formate buffer, to control pH and aid in the ionization of analytes. Uracil was
employed as an internal standard for the method because although it is not retained on a
reversed phase column, and is generally used in RPLC to calculate void time. However, uracil is
retained on a HILIC column.
5.3

Results
Previous assay results had illustrated an anomaly in the typical dose response curves of

positive allosteric GABAAR modulators, in that GABA did not need to be added to the assay to
activate the receptor. Ideally, this is a parameter of the assay which needs to be controlled, in
order to generate an accurate dose response curve for comparison with other drug compounds
of interest. Figure 44 shows the results of this assay with this anomaly, showing extremely
similar dose response curves for the compound with or without the presence of GABA.
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Figure 44. Calcium assay response of the lead asthma compound Xhe-III-74 acid in the presence of Jurkat
cells illustrating the similarity of results with or without the addition of [1 mM] GABA. Data: Amanda
Nieman.

The assay shows a response difference between GABA and GABA dosed with compound,
thus Xhe-III-74 acid is modulating [Ca]i. However, the addition of additional GABA did not
change the response significantly, which can only be explained by endogenous GABA already
present. Similar results were observed quantifying IL-2 protein by ELISA assay (Figure 455).
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Figure 45. Results from the IL-2 ELISA assay from Jurkat cell extract showed a reduction of IL-2 in the
presence of GABA and in XHE-III-74 acid and XHE-III-74 EE. However, no significant differences between
the both compounds in the presence and absence of GABA were identified. (Data: Gloria Forkuo.)

Thus, the amount of GABA in Jurkat cell media was quantified by HILIC-MS/MS. The cell
density was 3x105 cells/ml and the cell media analyzed directly with a triple quadrupole LCMS/MS instrument. Standards of GABA were prepared in triplicate and diluted serially to
generate the calibration curve.
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Figure 46. Calibration curve for GABA determined by HILIC/MSMS. R square = 0.9902.

The average of three aliquots of Jurkat media was found to have 87.385 ppb GABA (or
[0.847 μM]), with a relative standard deviation of 6.419%. The limit of quantification for this
method was defined determined to be 24 ppb, which is consistent with other recently
published articles quantifying the amount of GABA by HILIC methods.47 Although this method
was a brief component within this presented work, it illustrates the importance of
multidisciplinary knowledge within the drug discovery group.
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CHAPTER 6. Pharmacokinetic Studies
6.1

Introduction
Pharmacokinetic (PK) assays are used in drug development to study the absorption,

distribution, and elimination of a lead compound in vivo. This is done by quantifying the
amount of drug in biological samples at sequential time points, and using that data to generate
a pharmacokinetic curve. A plot of the general shape of a pharmacokinetic curve is shown in
Figure 477.1 In this generic representation, samples would be taken at each arbitrary time unit
and quantified using an analytical method, most commonly LC-MS/MS.

Figure 47. General representation of a pharmacokinetic curve.

Although PK data is traditionally generated from blood draws, the above curves can also be
generated from quantified amounts of compounds extracted from target organs. For example,
imidazobenzodiazepines in these studies are of interest to treat asthma, therefore it was
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important to quantify the amount of compound in the lung, as the lung is the target organ.48 In
addition, these compounds target GABAA receptors which are expressed in the brain, thus
quantification of compound in brain tissue was important to estimate adverse side effects by
the central nervous system. There are many known benzodiazepine compounds currently on
the market (such as the 1,4-benzodiazepine drugs alprazolam, diazepam, and many others) for
which the brain is the target organ. The primary difference between these known drugs and the
lead compounds presented in this work (which contain the same core benzodiazepine
structure) is the presence of key functional groups, attached to the core benzodiazepine
scaffold. The functional groups determine whether or not the compound can cross the blood
brain barrier and subsequently bind to GABAA receptors in the brain. In an effort to avoid any
cognitive side effects for the asthma compounds, low amounts of compound are desired in the
brain. Potential cognitive side effects are monitored using separate in vivo biological studies,
both here at UWM as well as with collaborators at Columbia University. One such assay, for
example, is the rotarod assay, in which mice are dosed with lead compound and tasked to run
on a cylindrical rod. If the compound acts as a sedative, the mice will fall off of the rod. To
avoid cognitive side effects which may have a negative impact, like sedation, it is important to
quantify the amount of compound in the brain.
Benzodiazepines are known to be well absorbed by the GI tract after oral administration.
They are highly protein bound and widely distributed in the body, typically accumulating in
lipid-rich areas (such as the CNS and adipose tissue). The more lipophilic the compound, the
higher the absorption rate and therefore the fastest the onset of clinical effects. There are
several parameters of merit that are of importance in pharmacokinetic studies, including the
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area under the pharmacokinetic curve (AUC), the time at which maximum compound is present
in the blood or target organ (Tmax), the maximum concentration reached at that time (Cmax),
and the rates at which the compound is both absorbed and eliminated. Similar to the
microsome stability and brain homogenate assays a first-order elimination is assumed that
enables the calculation of half-life based on the quantified amounts of drug in various tissue
types. The half-life is the time interval required for the concentration of the drug to decrease by
a factor of 0.5. As a general rule, a drug is said to be completely eliminated from the body after
a period of five half-lives.2 The half-life expression is showed in Equation 10.

Equation 10. The natural log of 2 divided by the elimination rate yields
the elimination half-life.

With regard to the concentration of compound in the blood, the compound can be
bound to protein and therefore carried to the target organ, or it can be on the road to
excretion. Therefore we are interested in the concentration as it relates to the protein bound
drug. The rate of elimination as a function of time can be used to express the protein-bound
concentration in a given sample as it relates to the initial protein-bound drug concentration, Cpo
as shown in Equation 11. The non-protein bound fraction of the drug will not reach the target
organ and generally will undergo excretion.

Equation 11.
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From these data, the rate of elimination can be shown as a first-order function of Cp. Clearance
is determined from a concentration vs. time plot, which allows for the direct calculation of the
area under the curve (AUC) with Equation 13.

Equation_12.

Equation 13.

From the AUC, the clearance can be calculated from the original dose and the area under
the curve, as shown in Equation 14.

Equation 14.

In addition to clearance, the volume of distribution is used to describe how a drug disperses
throughout the body. An assessment of the total volume in which a drug will be distributed is a
property of that drug, and is directly related to the elimination rate, the half-life, and the
clearance for the drug.

Equation 15.
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For the studies in this work, single-dose pharmacokinetic curves are generated by
quantifying the amount of compound present in samples by LC-MS/MS. A generic
representation of this curve is shown in Figure 488.

Figure 48. General image of a pharmacokinetic curve resulting from oral or i.p. dosing schedule.

However, orally delivered drugs must be absorbed from the digestive system first before
they can enter the bloodstream (which is where Cp is determined).37 Therefore, from these
curves we show both and absorption phase and an elimination phase. These relationships can
also be described by Equation 17.

Equation 17.

The variable F in the above equation is for bioavailability, which for an oral drug, depends
on the resistance to first pass metabolism in the liver. The variable EH in Equation 18 refers to
the hepatic extraction, therefore drugs with a high EH value have poor bioavailability.
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Equation 18.

In order to effectively plot all data points and calculate the parameters of particular
interest, we have implemented a software program called PK Solutions from Summit Research
Services.
The analysis of bioanalytical samples presents challenges with regard to the elimination of
matrix effects and species that interfere with analysis. These assays require highly sensitive
analytical methods capable of achieving very low limits of detection for quantification.
Obtaining low LOD and LOQ values can be achieved by increasing analyte signal, decreasing
background noise, or both. One of the challenges in pharmacokinetics studies can result from
the fact that complex biological matrices can create ion suppression issues in the mass
spectrometer, due to many endogenous compounds that co-elute with analytes of interest.
This is an inherently problematic shortcoming in LC-MS/MS analysis. Therefore, one of the
method development goals is to maximize the amount of analyte available for analysis, as well
as clean up the sample as much as possible to minimize matrix effects. PK studies require
efficient chromatographic and sample preparation strategies, not only for the reasons listed
above but also to facilitate the analysis of a large number of samples. The most commonly used
sample preparation techniques are protein precipitation (with an organic solvent, essentially
liquid-liquid extraction, or LLE) and solid phase extraction (SPE). Typically, extraction solvents
for LLE are non-polar organic solvents that are different from the starting mobile phase of an LC
method. Unfortunately, this disparity in polarity can lead to band broadening during
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chromatographic separations. It can also create unpredicted changes in retention times. The
most common way to remedy this issue in LLE sample preparation techniques is by evaporation
of the extraction solvent followed by reconstitution in mobile phase. This reconstitution step
allows for the flexibility to extract with any solvent desired rather than exclusively LC-MS
friendly solvents.
The other sample preparation approach, SPE, employs trapping the analytes in a
hydrophobic sorbent (such as a C18) on a separate “trap” column. The samples are injected
with an aqueous mobile phase to ensure that all of the hydrophobic analytes partition into the
hydrophobic trap. Provided that the analytes are hydrophobic as well (as is the case with the
imidazobenzodiazepines in these studies) they will partition preferentially into the trap column.
Meanwhile, any water soluble proteins, peptides, salts, and contaminants will be flushed to
waste. The analytes are then eluted from the SPE trap column with percentage of organic LC
solvents and carried to the traditional analytical column. This process yields significantly cleaner
chromatography given the absence of water-soluble interferences, which are endogenous to
complex biological matrices. Herein, methods for both sample preparation strategies are
presented, and results for several GABAA receptor modulators are presented.

6.2

Experimental Procedure
5-10 weeks old female Swiss Webster mice (Charles River Laboratory, WIL, MA) were used

for the experiments. Mice were housed under pathogen-free conditions, under standard
conditions of humidity, temperature and a controlled 12 hour light and dark cycle and had free
access to food and water. All animal experiments conformed to the rules and regulations of the
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University of Wisconsin, Milwaukee Institutional Animal Care and Use Committee (IACUC).
Female Swiss Webster Mice were dosed by interperoniteal (i.p.) injection with vehicle or test
compound formulated in DMSO/ propylene glycol/ PBS, 10:40:50, (v/v/v) and injected at a dose
of 5 mg/kg. At 3, 10, 15, 20, 40 60, 90 and 120 minutes groups of mice were euthanized and
blood (collected into heparinized tubes, 50 μL of 1 mg/mL heparin), lungs, and brain were
harvested and the sample were stored in liquid nitrogen until analysis.
Blood samples were thawed on wet ice, vortexed for 10 seconds, and a 100 μL aliquot
was taken and added to 400 μL cold acetonitrile containing [20 nM] internal standard (HZ-166),
which was of similar structure and had similar chemical properties. Samples were vortexed for
30 seconds and centrifuged at 13,000 RPM for 3 minutes. The supernatant layer was then
transferred to clean tubes and evaporated overnight. The residue was reconstituted with 300
μL of mobile phase and spin-filtered through 0.22 μm nylon centrifugal filter units (Costar).
After reconstitution, verapamil was added as a second internal standard to all samples as well
as calibration standards. 5 μL of the sample was injected to the LC–MS/MS 8040.
Brain and lung tissue samples were stored in liquid nitrogen prior to homogenization
and extraction. Whole organs were thawed over ice, weighed, and homogenized directly into
500 μL ACN containing an internal standard using either a Benchmark Scientific BeadBug
Homogenizer with three 3.2mm stainless steel beads, or a handheld LabGen T2 homogenizer.
Samples were homogenized for 30 seconds, centrifuged for 3 minutes at 13,000 RPM. This
process was repeated for a total of three extractions. The supernatants were combined and
prepared in the same manner as the blood samples for LC-MS/MS analysis.
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High performance liquid chromatography (HPLC) was performed with Shimadzu Nexera
X2 LC30AD series pumps (Shimadzu, Kyoto, Japan) that include a 20A5R degassing unit, SIL
30AC autosampler and a 20A column oven. Analytes were separated by a Restek Ultra Biphenyl
II column (2.1 mm × 50 mm, 5 μm particle size, Restek, California, US) under gradient elution at
a flow rate of 0.6 mL/min. The mobile phase consisted of acetonitrile for the organic ‘B’ solvent
and water for the aqueous ‘A’ solvent (both containing 0.1% formic acid). Time program: 10% B
→ 99% B (3 min), hold at 99% B (3.75 min), return to 10% B (4 min), hold (4.5 min). Column
Temperature: 50°C.
Analytes were monitored under positive mode by Shimadzu 8040 triple quadrupole
mass analyzer (Shimadzu, Kyoto, Japan) electrospray (ESI) and atmospheric pressure ionization
(APCI) run in dual (DUIS) mode. The fragmentation transitions are monitored in multiple
reaction monitoring (MRM) mode. Ion transition pairs for all analytes and collision energies are
listed in Appendix A. Collision energy is optimized for each transition to obtain optimal
sensitivity. The mass spectrometer was operated with the heat block temperature of 400°C,
drying gas flow of 15 L/min, desolvation line temperature of 250°C, nebulizing gas flow of 1.5
L/min, and both needle and interface voltages of 4.5 kV. The response acquisition was
performed using LabSolutions software.
HZ-166 was chosen as an internal standard for the extraction method because it has
similar chemical structure than the analyte and was therefore used to account for sample
dilution, evaporation, and matrix effects. Verapamil was used as a second standard to monitor
instrumental variations, both intra- and inter-batch. Stock solutions of all analytes were
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prepared at concentration of 2 mg/mL separately in ACN and stored in a −20° C freezer, with
the exception of carboxylic acid compounds, which were prepared in 80:20 ACN:water due to a
lack of solubility in pure organic solvent. Intermediate working solutions of each were prepared
by serial dilution with mobile phase (80:20, ACN:water with 0.1% formic acid). Calibration curve
solutions were prepared at concentrations of 1, 5, 10, 15, 25, 50, 75, 100, and 150 nM on the
same day as the analysis was performed.
The intra-run/within-run validation was performed for concentrations of 10, 25 and 75
nM with three replicates for each concentration. For separate validations, separate standard
curves were newly prepared. The standard curves were fit by a linear regression and the
validation samples were calculated back by the calibration curve of that day. The mean and the
coefficient of variance (CV) were calculated accordingly. Accuracy was calculated by comparing
calculated concentrations to corresponding nominal concentrations.
Quantified concentrations were then analyzed by a separate software program to
calculate pharmacokinetic parameter of merit. These parameters were calculated with PK
solutions software 2.0 and fitted to the following equation: c = A•e-at + B•e-bt + C•e-ct . Due to
the rapid absorption, two phases C = A•e-at + B•e-bt were sufficient to describe the
pharmacokinetic curve: distribution/absorption phase and elimination phase.
In an effort to increase throughput and decrease sample handling time, blood samples
were analyzed in parallel using an on-line solid phase extraction setup. Whole blood samples
were diluted 4x into acetonitrile and filtered with push filter vials (Thompson Instrument
Company, Oceanside CA) and placed directly into the autosampler for analysis by LC-MS/MS.
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Analytes were loaded onto a ‘trap’ column (Strata-X column, Phenomenex, Torrence CA) with
water at a flow rate of 0.1 mL/min. This is done using a third pump that is separate from the
two traditional binary HPLC pumps. The instrument is plumbed using two valves to change the
direction of the flow, which enables the binary pumps to elute the analytes from the trap
column to the analytical column (as shown in Figure 49). Polar compounds from the blood
samples such as small proteins or peptides will not be retained on the trap, and therefore will
stay in the water phase during the loading process. The HPLC mobile phase begins the gradient
method described above after the analytes have been given 3 minutes to load onto the trap
column, and then conventional reversed phase LC-MS/MS analysis occurs as described above.
Although the on-line SPE method requires additional analysis time on the instrument, it allows
for a great decrease in sample handling time, as there is no need for manual protein
precipitation with acetonitrile followed by evaporation and reconstitution in mobile phase.

79

Figure 49. Schematic of the on-line solid phase extraction and HPLC system, featuring four pumps, three
degassing units, two rotation valves, and an autosampler. Pumps A and B are typical gradient pumps for
HPLC, pump C is an HPLC pump for loading the trap column, and pump D is an extra pump for flushing
lines to waste. The directionality pictured above illustrates the valves in load position. This directionality
is reversed to send the eluate from the trap column to the analytical column.

6.3

Results
The initial development for the homogenization and extraction methods were applied

for the extraction of analyte from biological samples sent from the Emala group at Columbia
University. The initial lead compound, Xhe-III-74, was dosed via nebulized treatment to twelve
C57/BL6 mice using a 12.5 mM solution of lead compound with 12.5 mM diazepam in 50:50
ethanol:water. This initial distribution study aimed to identify whether or not the lead
compound was seen in various tissue types: lung, liver, brain, and also blood plasma. Before
attempting a full pharmacokinetic assessment, a method was needed to quantify these
compounds in various biological samples.
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Samples were weighed by difference into a 50 mL plastic conical tube. The tissue
samples were homogenized with twice the amount of water. The homogenizer barrel was
rinsed with two 650 μL portions of water, and the rinses were added to the mixture. The total
solution was extracted four times with 6 mL of diethyl ether (this volume was chosen because it
was approximately double the volume of the homogenate mixture). The ether layers were
combined and evaporated to dryness in a round bottom flask. The analyte was reconstituted in
5 mL methanol and sonicated to ensure all compound was dissolved. 1 mL of the analyte
solution in methanol was spiked with HZ-166 as an internal standard at [20 ug/mL] and
quantified on the triple quadrupole LC-MS 8040. Samples were ionized in DUIS mode, with 1.5
L/min nebulizing gas, 250° C desolvation line temperature, 400° C heat block. Drying gas flow
was 15 L/min. Analysis was completed with a method run time of 4.5 minutes with a
methanol/water gradient containing 0.1% formic acid in the mobile phase. Gradient
parameters: 10% B to 99% B (3 min), hold at 99% B (3.75 min), return to 10% (4 min), hold for
30 seconds; flow rate of 0.6 mL/min. Column was a Restek Ultra biphenyl column, 3 μm, 100 x
2.1 mm (with a 10 x 2.1 mm guard column). Retention times seen in this method were 2.8
minutes for HZ-166, 3.1 minutes for Xhe-III-74, and 2.9 minutes for Diazepam. Results for this
quantification are seen below in Figure 500.

81

Figure 50. Results of initial compound extraction study.

Although the standard deviation bars for this experiment were much higher than
desired, the main conclusion that can be drawn from this distribution study is that Xhe-III-74 is
better absorbed than diazepam, especially in the brain. This is interesting because diazepam is
known to cross the BBB and act upon GABAA receptors in the brain (the antidepressant Valium).
However, it is also well known that diazepam is actually a pro-drug and is metabolized to
nordiazepam, an active metabolite that is also able to pass the BBB. This metabolism is shown
in Figure 511.
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Figure 51. Diazepam and its active metabolite, nordiazepam.

Because the triple quad detects compounds by mass it was necessary to develop an
additional LC-MS/MS method to detect nordiazepam. Thus, the concentrations of nordiazepam
were quantified and combined with the concentrations for diazepam to create Figure 522.

Figure 52. Modified graph including the quantification of diazepam and nordiazepam (denoted DzNz for
both compounds together).

The comparison between Figure 50 and Figure 52 showed a small increase of the
identified amounts of diazepam and nordiazepam. However, the distribution of XHE-III-74 is still
superior to that that of diazepam.
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Although this method was very thorough and was able to yield over 90% recovery via
liquid-liquid extraction, the volume of organic solvent consumed was considerable. In addition
to the cost of the solvent, this procedure must be performed in a fume hood due to the fumes
of diethyl ether. Therefore, this method was not appropriate for high-throughput quantification
for a large number of samples.
In an effort to miniaturize this method, tissue samples were transferred to flat bottom 2
mL tubes as opposed to 50 mL conical tubes. The tissue samples were then homogenized
directly with organic solvent, as opposed to being homogenized in water and then extracted
with organic solvent. This in essence creates a form of solid-liquid extraction, as the solid organ
is homogenized with the liquid organic solvent. An internal standard of similar structure was
spiked into the organic solvent prior to homogenization (e.g. HZ-166 in acetonitrile). These
procedural changes allow for a significant decrease in solvent usage as well as a decrease in use
of consumable materials (50 mL plastic tubes). The transfer of these samples from large conical
tubes to smaller Eppendorf tubes also allows for the use of multichannel pipettes, which is
helpful when preparing a large number of samples, to dispense the homogenization solvent
with internal standard. It is also noteworthy that the large surface area of the 50 mL conical
tube creates room for transfer error, as there is more solvent being transferred which requires
multiple aspirations with a pipette.
The first in vivo study completed with the miniaturized procedure was Xhe-III-74 Ethyl
Ester. The compound was dosed by IP injection as described above. Xhe-III-74 Ethyl Ester was
quantified in brain, lung, and blood samples, as shown in Figure 533.
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Figure 53. Pharmacokinetic analysis of Xhe-III-74 Ethyl Ester.

Table 5. Pharmacokinetic parameters of interest for the PK study of the Xhe-III-74 Ethyl Ester.
Figure of Merit

Blood

Lung

Brain

Cmax (ng/ml)

216.9

120.7

84.8

Tmax (min)
AUC (ng*min/ml)

10
5737.0

3
3358.0

40
4516.0

T1/2,E (min)

16.3

17.6

22.9

T1/2,D (min)

26.6

2.2

36.7

Although Xhe-III-74 Ethyl Ester is rapidly absorbed and distributed, the concentrations
seen in the brain are higher than desired for an asthma lead compound. Because hydrolyzed
products are commonly seen in first pass metabolism, a carboxylic acid product was
hypothesized to be created in vivo for this compound, as seen in Figure 544. The original
samples that were dosed with the Xhe-III-74 Ethyl Ester compound were then re-quantified in
search of the acid analog.
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Figure 54. Conversion of Xhe-III-74 Ethyl Ester to the Xhe-III-74 Acid by hydrolysis in vivo.

Figure 55. Pharmacokinetic curve for the Xhe-III-74 Acid in brain, lung, and blood samples. The animals
were originally dosed with the Xhe-III-74 Ethyl Ester, therefore this acid compound is a metabolite.
Table 6. Pharmacokinetic data for the acid metabolite of the Xhe-III-74 Ethyl Ester. nd indicates not
determined due to the compound concentration being less than the lower limit of quantification.

PK Parameters

Blood

Lung

Brain

Cmax (ng/ml)

102.3

<LLOQ

<LLOQ

Tmax (min)
AUC (ng*min/ml)

10
4282.3

nd
nd

nd
nd

T1/2,E (min)

11.6

nd

nd

T1/2,D (min)

2.8

nd

nd

As the PK curve shows, the acid compound is not seen in the lung or the brain in any
appreciable amount. It is also noteworthy that the AUC for the acid metabolite is very similar to
the AUC for the Ethyl Ester compound, illustrating an equally effective distribution. Therefore,
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the next logical step was to dose the mice directly with Xhe-III-74 acid, as opposed to rely on in
vivo metabolism. This data is presented in Figure 566.

Figure 56. Pharmacokinetic study for the Xhe-III-74 acid analog, dosed in the same manner as the XheIII-74 Ethyl Ester.

Xhe-III-74 Ethyl Ester acid displayed good distribution in the blood and lung, as well as a
lack of absorption in the brain. However, the compound was cleared or metabolized very
rapidly from both the blood and the lung, so although it appears to have a fast onset the
clearance is too rapid for a good asthma drug. The goal following this PK study was to screen
additional compounds to identify a compound that does not cross the BBB and is cleared
slowly.
An inherent challenge presented by thorough in vivo studies is the immense time it
takes to procure samples and the number of mice. Therefore it is difficult to screen many
compounds with this method. In addition, the sample preparation as described above is timeconsuming. Although the miniaturization of this method was helpful for the throughput of
samples as compared to LLE with diethyl ether, the manual homogenization step with the handheld homogenizer is a bottleneck step in and of itself, as the barrel must be thoroughly cleaned
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between samples to avoid cross contamination. To eliminate this bottleneck issue and
eliminate the risk of cross contamination between samples, several automated bead-based
homogenizers were tested to investigate if the manual homogenizer could be eliminated.
The Omni BeadRuptor is a beadmill that uses ceramic, metal, glass, garnet, or carbide
beads for homogenizing 24 samples simultaneously. The BeadBug is a much lower power tool
that uses zirconium or steel beads to homogenize 3 samples simultaneously. Several bead types
were tested first with the BeadBug, as this was a relatively inexpensive tool (Figures 57 and 58).

Figure 57. Brain extractions using the BeadBug tool.

Figure 58. Lung extractions using the BeadBug.

The zirconium beads were not strong enough to homogenize the lung tissue, therefore
they were excluded as an option. Although the garnet and ceramic beads were able to
homogenize the lung and brain tissue, the stainless steel beads were found to have a greater
percentage of compound extracted within the first extraction. Therefore the stainless steel
beads were chosen for future investigation. The Omni BeadRuptor was borrowed from Thermo
Fisher Scientific for testing, with stainless steel beads used as the homogenization medium. The
BeadRuptor yielded similar results to the BeadBug.
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Figure 59. Homogenization methods overall comparison.

Although the bead homogenization tools appeared to yield higher extraction results in
the first extraction, ultimately a second extraction is still required to achieve greater than 90%
extraction efficiency. Therefore, there is no significant difference between the bead-based
homogenizers and the manual homogenizer. The main advantage that the bead tools provide is
that they eliminate cross contamination between samples. However, the time to load the tubes
and beads, and then recover the beads, does not actually decrease the sample preparation
time. This added time would be worth it if this method was able to yield close to 100% recovery
in one extraction, but this is not this case. In addition, these tools create an added cost in the
beads, the specialized tubes, and the instruments themselves. Therefore we proceeded with
hand-held homogenization at this time.
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The liquid-liquid extraction method as listed previously is an inexpensive, robust, and
uncomplicated method that is being used by several MIDD members. However, for the analysis
of blood samples, an on-line solid phase extraction method was also tested. The advantage of
this method for blood samples is the “dilute and shoot” capability provided. The method
utilized the reversed phase cartridge to trap the analytes, and then they were eluted from the
trap with the HPLC mobile phase. Figure 611 illustrates the comparison between both methods
using samples for a PK study with MRS-01-66 (Figure 60).

Figure 60. Structure for MRS-01-66, the dimethyl amide analog to Xhe-III-74.

Figure 61 SPE vs. LLE data for blood samples, from the PK study of MRS-01-66. The variances seen are
not statistically different. The means are only statistically different at the end time points (60, 90, 240
minutes), which are at quantities <LLOQ.
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That the two methods (SPE vs. LLE) are not statistically different and either method is
acceptable for the analysis of whole blood samples on the triple quadrupole LC-MS/MS
instrument. Quantified amounts were compared at each time point first with the two-tailed t
test, and then with the f test, to illustrate no significant differences in both the means as well as
the variances for the measurements. Thus, SPE and LLE methods yield very similar results.
However, the SPE cannot be used for whole tissue samples because the samples cannot be
injected, as solids, onto the LC-MS instrument.
Our collaborators in the Cook group have synthesized the dimethyl amide compound
MRS-I-66 to explore the differences between esters and amides for the imidazobenzodiazepine
scaffold. As it is the case with the Xhe-III-74 Ethyl Ester, such compounds might hydrolyze to the
corresponding acid. We observed in the microsome stability assay that esters and amides with
longer and more branched carbon chains are metabolically less stable than their short carbon
chain analogs. The result of the PK analysis for MRS-I-66 is depicted in Figure 622.
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Figure 62. PK graph for the dimethyl amide compound.32
Table 7. PK results for MRS-01-66

Figure of Merit

Blood

Brain

Lung

Cmax (ng/g)

691

123

30

Tmax (min)
AUC (ng*min/ml)

3
6205

10
2701

3
764

T1/2,E (min)

8.8

10.3

11.7

Erate (min-1)

0.078

0.067

0.059

Interestingly, MRS-01-66 displayed a rapid onset and also a rapid clearance. The amount
of compound found in the lung, however, was far less at 30 ng/g. For these reasons, the MRS01-66 compound was not pursued as the primary lead compound for the asthma project.
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3.2 Results for GLO1 Inhibitors
Methylglyoxal is a non-enzymatic side product of glycolysis, catalyzed by a cytosolic
enzyme, GLO1.49 The compound is inversely proportional to the enzymatic activity of GLO1, and
has been shown in primary neuronal cultures to act as a competitive partial agonist for the
GABAA receptor.50 An overexpression of this enzyme in mice has been shown previously to
increase symptoms of anxiety and depression, but when dosed with methylglyoxal or a direct
inhibitor to GLO1, these symptoms were decreased.49a Therefore, we investigated the potential
of GLO1 inhibitors as antidepressants.51 Mice were dosed with i.p. injection as described above,
and the samples prepared in the same manner as the compounds for the asthma project (LLE
for the blood samples and manual homogenization for the tissues).
Initially, the analyte pursued for detection in this study was the original GLO1 inhibitor
pBBG, shown in Figure 633. However, the compound was not found in the blood samples by LCMS/MS analysis. Employing a similar strategy as above, we searched for a metabolite. Although
the parent compound was not identified in the samples, the diacid metabolite was identified
and quantified. The structure for this metabolic transition is illustrated in Figure 633. This
metabolite was produced in vivo by hydrolysis.
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Figure 63. Transition of pBBG compound into the diacid analog, proposed to occur in vivo.

Figure 64. PK graphs for pBBG diacid and MeGFN in the brain.
Table 8. Calculated PK parameters for two GLO1 inhibitor in the brain.

The published results for the GLO1 project show the potential to produce fast acting
antidepressant effects. The most straightforward explanation for the observed antidepressantlike effects is that GLO1 inhibition increases MG concentrations. MG is a competitive partial
agonist at GABAA receptors, and depression is associated with reductions in cerebrospinal fluid
GABA levels as well as the number of GABAA receptors in cortical regions. In addition, chronic
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antidepressant treatment correlates with an increase in GABA, supporting a potential role for
GABAergic signaling in depression. The effects of GLO1 inhibitors on GABAergic signaling is
distinct from any other GABAAR-acting compounds (such as benzodiazepines like alprazolam).
MG acts as a competitive partial agonist at GABAA receptors, thus modulation of MG
concentrations by GLO1 inhibitors may have different effects as compared to other GABA ARacting compounds.
Previous studies have shown that genetic and pharmacological GLO1 inhibition, as well as MG
administration, are anxiolytic, have anti-seizure effects and reduce ethanol consumption. The
current results show that GLO1 inhibition might provide a unique strategy for treating
depression with comorbid anxiety, epilepsy or alcohol use disorders, which would constitute a
unique class of therapeutic compounds and would address an urgent need, given the high
comorbidity of these disorders. Our findings suggest that modulation of GABAAR signaling may
be a promising approach for the development of fast-acting antidepressants.

6.4

Conclusions
The importance of high-throughput analyses in drug discovery cannot be overstated. In

an effort to speed up the sample preparation process as well as increase reproducibility, several
homogenization methods were compared, several extraction methods were tested, and every
opportunity to exploit rapid analyses was taken advantage of for these studies. Although the
stainless steel bed homogenization method was able to yield comparable results to the manual
homogenizer, the added cost of materials and equivalent sample preparation time did not
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make this an advantageous option. However, the miniaturized extraction method with
acetonitrile or methanol employed as the extraction solvent is sufficient for our analyses, as the
analytes quantified in this work are all soluble in one or both of those solvents. Thus, the need
for diethyl ether is eliminated. In addition, the on-line solid phase extraction continues to be
implemented for studies within the MIDD due to increased purity of the sample and decreased
sample preparation time for liquid matrices. We have created the capability for the MIDD to
establish a full pharmacokinetic profile for any lead compound of interest, and this assay has
been repeated multiple times for various compounds to qualify drug candidates for further
testing. If additional funding becomes available in the future, the Omni Bead Ruptor 24 could
be re-visited as an option for tissue homogenates, including tissues other than brain and lung
such as liver, kidney, small intestine, or any other pertinent organs important to drug discovery
projects. The utility of solid-phase extraction can also be employed in an off-line manner, with
96 or 364 well plates. This could be employed for metabolomics studies on the IT-TOF, which
does not have an on-line solid phase extraction setup. It would be interesting not only to
quantify the parent compound from drugs dosed in pharmacokinetic studies, but also to
identify new metabolites in various tissue types.
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CHAPTER 7. MALDI imaging mass spectrometry (MALDI IMS)
7.1

Introduction
Matrix assisted laser desorption ionization (MALDI) mass spectrometry had been widely

implemented as a method to investigate large biomolecules, notably proteins and peptides that
are too large to be analyzed with conventional LC-MS instruments. For example, a protein with
a mass of tens of kilodaltons is far too large to be analyzed by a quadrupole mass analyzer
(which typically has a maximum around 5,000 m/z with a reasonable scanning speed) without
first being digested into small peptides by an enzyme such as trypsin. In the last decade, MALDIMS has come to the forefront in small molecule analyses, particularly as a method to analyze
drugs or other small molecules in complex biological samples, such as whole cells and tissue
sections without using extraction procedures. MALDI-MS also shows promise in diagnostic
imaging (MALDI IMS), potentially identifying and localizing markers for diseases like cancer.52
One distinct advantage of MALDI IMS as an imaging tool is that it is a label-free allencompassing technique, which doesn’t require antibodies or expensive and hazardous
radiolabels. MALDI IMS has diverse application to many different analyte types and research
areas, including but not limited to the study of new and existing proteins, peptides, nucleic
acids, small molecules, and even polymers.53 Herein, we present a method developed to image
drug compounds in tissue slices, employing collision induced dissociation to identify
compounds of interest based on known fragmentation patterns. The mass detector employed
for MALDI IMS is a Dual Time of Flight (TOF) analyzer with a collision cell that enables increased
specificity with the generation of daughter ions (Figure 65).
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Figure 65. Shimadzu 7090 MALDI-TOF/TOF instrument schematic.

The instrument used in this work employs a 2kHz UV laser (355 nm) for ionization. The
instrument is also equipped with a dual wire-grid ion gate, to gate species that may be close ion
nominal mass, and produce distinct fragment ion spectra. High mass resolutions (10,000
FHWM) are achieved by a combination of pulsed extraction, the ion optics, and axial spatial
distribution focusing. When employing MSMS mode, the ions enter a collision cell at 20keV,
which is a high-energy collision induced dissociation method with helium as the collision gas.
The instrument is also capable of fragmenting ions in a low-energy manner. In this variation,
the collision gas is not used, and so the ions detected are the result of spontaneous metastable
decay of the precursor. The two differing fragmentation methods generate different fragments
which can garner useful information about the analytes (for example, peptide side-chain and
lipid backbone fragments will only be generated by high-energy CID).
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In Matrix-Assisted Laser Desorption Ionization (MALDI), a low molecular weight matrix is
mixed with the sample and allowed to crystallize. The crystalline matrix absorbs UV energy
from the laser, and also aids to ionize the analytes (hence the term, matrix-assisted). There are
many matrix options commercially available, however, the matrix selections chosen for this
work are common for small molecule analyses.
Matrix selections:

CHCA (α-cyano-4-hydroxycinnamic acid)

DHB (2,5-dihydroxybenzoic acid)

DHA (2,5-dihydroxyacetophenone)

The MALDI technique is based on laser irradiation, which induces desorption and
ionization of the analyte of interest as a molecular species ([M+1] or [M-1]).
MALDI IMS generates an ion density map or “heat map” in which more brightly
appearing areas indicate a higher abundancy of a specific ion that particular location.
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Therefore, the technology gives us valuable information regarding the spatial distribution e.g. a
drug distribution in a particular tissue. The spatial resolution in MALDI IMS is dependent on the
laser beam focus (including diameter and space between laser shots), the size of the crystal
matrix, and the diffusion or delocalization of analytes during the sample preparation process. 54
The localization of compounds in a specific target tissue has valuable information in regards to
the interaction of drug and protein target.55 Pharmacokinetic studies have shown that
imidazobenzodiazepines distribute in the lungs (which is the target organ for our asthma
project) by quantification of lung homogenates using LC-MS/MS. Herein, a method is presented
to image the localization of imidazobenzodiazepines in mouse lung tissue slices.
Although the ion density map generates valuable information regarding localization of
ions of interest, the information can be enhanced when combining it with histological stains.
Sections can be taken in serial fashion, thereby making the differences between the sections
equivalent only to the thickness of the tissue section (for example, 12 micrometers). The
histological stain gives morphological information about the tissue, which can aid in the
explanation of why certain areas of the MALDI image may show high or low ion density. For
example, if there is a large gap in the ion density map of the lung, the histological stain might
show the absence of tissue such as a large airway or blood vessel. The hematoxylin and eosin
stain will show the nuclear contents as blue-purple, and red blood cells, non-nuclei, and
extracellular material will be pink. An example of the H&E stain is presented in Figure 66,
showing an airway for mouse lung tissue sliced at 12 µm thickness.
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Figure 66. H&E stain of mouse lung, showing the airway morphology.

In order to visualize the target protein of a small molecule, immunohistochemistry can
be employed using specific antibodies in conjunction with enzymatic or fluorescent detection.
Indirect immunohistochemistry methods employ an unlabeled primary antibody to bind to the
target antigen, in this case the α5 subunit of the GABAA receptor. A labeled secondary antibody
interacts specifically with the primary antibody and enables detection of the receptor. Two
labels were used to image the alpha 5 subunit of the GABAA receptor. Firstly, horseradish
peroxidase protein (HRP), which is an enzyme that catalyzes the oxidation of specific substrates
in the presence of hydrogen peroxide, resulting in a colored product. The substrate used for
HRP was 3,3’-diaminobenzidine (DAB). DAB reacts with HRP in the presence of peroxide to yield
an insoluble brown-colored phenazine polymer at locations where peroxidase-conjugated
antibodies are bound to the tissue.
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Figure 67. Cartoon of the reaction of horseradish peroxidase and DAB substrate to produce brown
coloration in tissue stains. (Image: AbCam.)

Secondly, a fluorescent small molecule can be attached to the secondary antibody, and
its fluorescence signal measured rather than visualizing the product on an enzymatic reaction.
Fluorescein and Cy5, both very common fluorescent dyes used for the immunohistochemistry,
were attempted for the immunofluorescence stain of the α5 receptor.

Figure 68. Dyes used for immunofluorescence. FITC shows excitation and emission at 495 nm
and 519 nm, respectively, and Cy5 Ex: 650nm, Em: 667nm.
4,6-Diamidino-2-phenylindole (DAPI) was used to stain the nuclei of all cell Figure 69.
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Figure 69. 4,6-Diamidino-2-phenylindole DAPI Ex: 358 nm, Em: 461 nm.

DAPI is a di-cation at physiological pH and becomes strongly fluorescent when bound to
double-stranded DNA in the nucleus. The interaction with RNA is weaker thus the resulting
fluorescence is less pronounced for RNA.
The combination of MALDI-MS, H&E stain and immunohistochemistry can illustrates
valuable information of how a compound is distributed in vivo. MALDI IMS can also be used to
investigate metabolites generated through xenobiotic metabolic processes in the animal, as
well as adducts generated by the mass spectrometer itself. Investigative results will be
presented herein.

7.2

Materials and Methods

7.2.1 MALDI IMS
MALDI matricies were purchased from Sigma Aldrich (St. Louis, MO, USA): α-Cyano-4hydroxycinnamic acid #70990; 2,5-dihydroxybenzoic acid #85707, 2,6-Dihydroxyacetophenone,
#37468. MALDI calibration kit was also purchased from Sigma Aldrich (ProteoMass™ Peptide
and Protein MALDI-MS Calibration Kit, MSCAL) and used for calibrations according to the
package insert. Metal slides were purchased from Shimadzu Scientific (Japan).
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Swiss Webster female mice were dosed with 25 mg/kg compound via oral gavage and
sacrificed as according to the Tmax determined in previous PK studies. Mice were sacrificed by
CO2 and spinal cord dislocation (IACUC protocol 16-17 #25). Tissues were procured immediately
and exposed to dry ice vapor for five seconds followed by dry ice to freeze. Lungs were stored
at -80°C until cryosectioning with a Leica cryostat. Just before cryosectioning, lungs were
allowed to equilibrate to -20°C for 30 minutes. Lungs were sectioned at 20 micron thickness
and thaw-mounted to metal slides. Slides were allowed to come to room temperature in a
desiccator for 5 minutes, gently rinsed with water containing 0.1% TFA to remove salts, and
allowed to dry again at room temperature before matrix application. Matrix was applied using a
manual spray coating method with a TLC sprayer. 10 mL of matrix solution at 50 mg/mL was
passed at 3 psi using nitrogen gas. Matrix was allowed to dry fully between passes. The spray is
wet enough to extract analytes from the solid sample into the matrix, but dry enough to rapidly
crystallize and prevent delocalization of the analytes’ spatial locations. The TLC sprayer is slowly
passed approximately 12 inches in front of the sample plate, which hangs vertically in the fume
hood. Each pass applies a small amount of matrix, therefore the passes are repeated until all of
the solution is used up and the samples are sufficiently coated.
7.2.2 H&E stain
Fresh frozen tissue sections were taken in serial fashion (to the sections used for MALDI IMS) at
12 μm thickness and stored at -80°C prior to staining. Sections were rehydrated in the following
sequence: 30s in 95% ethanol, 30s in 70% ethanol, 30s in Milli-Q water. Slides were stained in
hematoxylin stain (VWR, 95057-844) for 1 minute, followed by rinsing in Milli-Q water for 3
minutes, and again 30s in 70% EtOH and 30s in 95% EtOH. Sections were then stained for 30s in
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eosin stain (VWR 95057-848), and subsequently cleared for 30s in 95% EtOH, 30s in 100% EtOH,
and 2.5 min in histoclear clearing solution (VWR 64110-04), which is a substitute for the
traditional clearing reagent xylene. After drying, 1 drop of Permount adhesive (VWR 100496550) was placed on each section and covered with a glass cover slip. Slides were allowed to dry
overnight before viewing under light microscopy.
7.2.3 Immunohistochemistry:
Mouse lung sections were taken at 12 micron thickness in serial fashion to the slides for the
MALDI and for H&E staining, and placed on glass microscope slides. Frozen section slides were
stored at -80°C in a sealed slide box. Just before staining, slides were allowed to equilibrate to 20°C. Slides were fixed for 10 minutes in cold 4% paraformaldehyde solution and allowed to
warm to room temperature. Antigen retrieval was performed by placing the slides in 10 mM
sodium citrate buffer at pH = 6.0 in a pressure cooker at 15 psi for 10 minutes. Slides were then
rinsed with PBS and a PAP Pen was used to create wells for the liquid on the surface of the glass
slides. Slides were subsequently washed with TBS Tween for 5 min, peroxidase suppressor
(Thermo Fisher Scientific, 35000) for 15 min, and twice more with TBST for 5 minutes. The
peroxidase suppressor reduces the background signals generated from endogenous
horseradish peroxidase in the tissue. Slides were then washed with background sniper for 10
minutes to block nonspecific staining resulting from the antibodies binding to proteins other
than GABAARs. Slides were washed twice more with TBST before incubation with the primary
antibody. Antibodies were diluted 1:100 and 1:250 with superblock T20 buffer as the diluent.
The slides were incubated overnight in the 4 degree. Wet paper towels were placed inside the
slide holder to retain moisture and prevent the glass slides from drying overnight.
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Following overnight incubation, slides were washed three times with TBS Tween for 6 minutes.
The secondary antibody was diluted in the same manner as the primary antibody and was
applied to the slides at room temperature and allowed to incubate for 40 minutes. Slides were
again washed three times with TBST for 6 minutes. Following the washes the chromogen DAB
substrate, which was diluted 10-fold into peroxidase substrate buffer and applied to the slides
for 6 minutes. Slides were washed with ddH2O for 5 min and counterstained with Hemotoxylin
solution for 1.5 min to stain the nuclei. Slides were rinsed with ddH2O and dehydrated through
4 changes of alcohol solutions (95%, 95%, 100% and 100%). Finally, slides were cleared in 3
changes of histoclear and coverslipped using permount mounting solution.
For the fluorescent immunohistochemistry stains, the same procedure was followed, except
rather than fixing the tissue and performing antigen retrieval, which is necessary to preserve
the tissue for an overnight incubation step, this step was omitted and the tissue was incubated
rather for 1 hour at room temperature (with the primary antibody). Silane coated microscope
slides (NC9968319, Fisher Scientific) were also implemented to improve the adherence of the
tissue to the slides. The simplified procedure consisted of rehydration in PBS for ten minutes,
PAP pen to create wells, blocking non-specific background staining with background sniper or
5% animal serum, washing with PBS, application of the primary antibody with 60 minutes
incubation, washing, application of the secondary antibody with 30 minutes incubation,
washing, application of 1.5 μg/mL DAPI for 10 minutes, two final washes with TBST and
coverslipping with Prolong Gold anti-fade reagent.

106

7.3

Results & Discussion
The method development process for MALDI IMS is very involved, including optimization

steps required at several stages: the in-vivo dosing of the animal, the sample preparation of the
tissue, the matrix selection and deposition, instrument conditions, and finally, image resolution.
The ADME property of a drug determines how a test animal processes a compound and which
concentrations can be found in biological sample at a particular time point. For MALDI IMS, high
tissue compound concentrations are necessary due it’s desorption process, which is
significantly less sensitive than quantification of tissue extracts by triple quadrupole LC-MS/MS.
The matrix application plays an important role in this. Typical matrix concentrations are 20-100
mg/mL, which by far exceeds the expected concentration of the analyte. The large matrix
concentrations in turn cause interferences in the TOF analyzer. Purification of the sample is
challenging and often not seen in MALDI IMS, especially with small molecule imaging. Samples
used for small molecule imaging experiments cannot undergo extensive washing steps, because
the analytes can delocalize from their original location or be washed away completely. The
introduction of high levels of matrix also presents challenges regarding signal suppression,
which are enhanced as compared to typical LC-MS analysis. For the MALDI IMS experiments
presented herein, a full pharmacokinetic profile of each compound was established first by LCMS/MS to determine the Tmax. In a separate experiment, dosed animals were sacrificed at that
specific time point to ensure high compound concentrations.
The matrix deposition process is, in and of itself, a broad field of study in MALDI IMS.
The most common methods employed are sublimation, spotting via micropipette or an
automated liquid distribution system, and spray coating, which can be automated with a spray
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instrument, or performed manually using a TLC sprayer or an artistic sprayer. The most rapid
and cost effective option was determined to be manual spray coating.
Matrix selection for each compound presents another unique challenge for MALDI IMS
because although one can easily optimize a matrix for pure compound by spotting the
compound directly with various matrixes followed by analysis, the results may not translate to
imaging experiments with tissue samples. One reason for this is that the matrix interferences
presented by a complicated sample like a tissue slice cannot be predicted or adequately
assessed beforehand. Therefore, the optimization of matrix selection needs to take place using
actual tissue. It is ideal to take one tissue and serial section it so that the comparison of matrix
choices are under comparable experimental conditions. An image of the workflow for the
sample preparation prior to MALDI ISMS is shown in Figure 70.
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Figure 70. MALDI IMS workflow. Images presented in this chapter were generated from a compound
synthesized by Guanguan Li of the Cook research group. Pharmacokinetic study was performed
previously by Revathi Kodali and Nick Zahn, as published previously.56

7.3.1 MALDI IMS results using MS/MS mode
Initial method development was performed on a manual spot of the analyte, for
verification that the analyte is in fact ionized by MALDI. Manual spotting also allows us to
ascertain the masses of fragments generated in MS/MS mode (similar to the method
development process on LC-MS/MS instruments) prior to actual sample analysis. A table of
fragments generated via both ionization methods is listed in appendix a. Figure 71 shows a
typical spectrum for the MALDI in MS/MS mode for the SH-053-2’F-R-CH3 acid compound.
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Figure 71. MALDI-MS/MS spectrum of the SH-053-2’F-R-CH3 acid spotted with DHB as the matrix.

Although generally speaking many of the same fragments are generated by collision
induced dissociation in both MALDI-TOF/TOF and ESI-MS/MS, there can certainly be differences
in fragmentation patterns. Initial lung section images were generated based on the transition
of m/z 360 [M+1] to m/z 316 fragment common to both ionization methods (Figure 72).

Figure 72. Lung section imaged for the 360>316 transition in MALDI-MS/MS. MSI import 200-400 bin
size 3, 5905 data points, 54.1843 MB, 62x74x51500 dpi and H&E stained serial tissue section.

The initial MALDI IMS image produced an unexpected result, showing what appears to
be an outline of the lung tissue section. This raises concerns of validity for this experiment
because we know this compound is localized in the lung and binds GABA AR alpha 5 receptors,
which are believed to be located in the airway of the lung.48 Thus, the image above must be the
product of either wrong sample preparation or wrong analysis.
Another important sample preparation consideration is the limited options for purifying
the sample. One such option is washing the tissue, in an attempt to de-salt the sample and
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eliminate interferences. Without this step, the analyte was only detected around the edges of a
tissue section of interest. However, with the addition of a gentle washing step, the analyte then
appears throughout the tissue section, which more closely correlates with the target receptor
in the tissue (Figure 73).

Figure 73. Comparison of unwashed vs. washed lung tissue sections in MALDI IMS using the 360>316
transition.

The washing step improved the signal for SH-053-2’F-R-CH3 acid not only due to the
removal of potential interferences, but also by removing SH-053-2’F-R-CH3 acid from the edge
of the slice that may have been delocalized during the sample preparation process. The
cryosectioning for the lung tissue sections was performed at -20°C. However, the matrix
application was performed at room temperature. Therefore, before application of the matrix, it
was necessary to equilibrate the slides from -20°C to RT. The issue presented is that taking a
metal slide from a freezer and bringing it to room temperature results in condensation across
the entire slide. As a water layer forms, the small droplets have the ability to move the analytes
of interest from their original location, potentially leeching out of the tissue sample and onto
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the slide. This coupled with fact that the tissue slice is a slightly raised on a rough surface
compared to a smooth, flat metal slide, resulted in the formation of a ring of condensation
around the edges of the tissue section. In attempts to avoid this condensation issue, slides are
placed in a desiccator to equilibrate to temperature. This alone, however, did not solve the
edging issue. Adding a washing step to uniformly remove all of the condensation prior to matrix
application appears to solve the issue of the compound appearing only along the edges of the
tissue section. Using this methods to other transitions of SH-053-2’F-R-CH3 acid were analyzed
using serial tissue slices (Figure 74)

Figure 74. Images of two lung tissue sections of SH-053-2’F-R-CH3 acid dosed mice at 360>283 m/z and
360>301 m/z transition, respectively.

The fragments imaged in Figure 74 are reproducible in imaging the SH-053-2’F-R-CH3
acid, and are seen in every dosed tissue section. It is important to note that these masses are
not present in tissue section prepared from vehicle dosed animals under the same
experimental conditions, as illustrated in Figure 75.
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Figure 75. Comparison of lung tissue from vehicle and SH-053-2’F-R-CH3 acid dosed mice. These sections
were taken using the same MS/MS method 360>283 m/z. Both samples were prepared on the same day
with the same matrix solution and application.

Compared with the tissue from non-treated mice, SH-053-2’F-R-CH3 acid was present in the
lungs and distributed throughout the tissue.
For any MS/MS technique, it is imperative that the method utilize reproducible
fragmentation of the analyte, to ensure that the compound is identified correctly. This high
level of specificity holds true for MALDI IMS, with the ability to distinguish the analyte from
other compounds. The Shimadzu 7090 instrument also employs a reflectron after the flight
tube, which is useful for the detection of low molecular weight analytes, as they can be difficult
to separate in TOF analysis. These compounds travel very quickly down the flight tube impeding
separation by time limited by the fight path. The reflectron enables additional separation by
increasing the flight path. The instrument tuning varies when employing the reflectron in MS1
mode vs. MS/MS mode. For larger masses, the tuning is set in linear mode. For small masses
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with no fragmentation, the tuning is set in reflectron mode. For small masses with
fragmentation, the tuning is set in reflectron MS/MS mode. The parameters for each
instrument mode are shown in Figure 77, linear mode, reflectron mode, and reflectron MS/MS
mode. Although the parent compound can be detected using MS1 mode, the MS/MS
capabilities increase this specificity and therefore yield a better spatial resolution for the
location of the analyte (Figure 76).

Figure 76. [M+1] ion image for the lead compound (SH-053-2’F-R-CH3 acid) in reflectron mode and
fragmentation 360>282.932 m/z in reflectron MS/MS mode.
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Figure 77. Tuning settings for the linear, reflectron, and reflectron MSMS modes of the MALDI-7090.
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When the ion density map is compared with microscope images of stained tissue, the
morphological information yielded by H&E stain allows for rationalization of patterns within the
ion density map. In Figure 78 below, it can be seen that any sparse areas within ion density
map, or “holes” where the compound is not present are actually a result of the serial section
lacking tissue in that particular area. When viewing the ion density map alone, it may appear
that the compound is not evenly distributed in the lung. However, when viewing the H&E stain
in parallel, it is clear that this is not the case.

Figure 78. Light microscope image of lung tissue stained with H&E (4x magnification) and MALDI IMS
image of the daughter ion in a serial tissue section (transition 360>282.930).

MALDI IMS presents an additional unique challenge in that the sample preparation
strategy employed for one analyte may not necessarily translate to another analyte. One
example is compound GL-II-93. Initial images acquired presented the same challenges as SH053-2’F-R-CH3 acid, showing what appeared to be an outline of the tissue section, as opposed
to consistent distribution throughout the lung section.
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Figure 79. Two separate lung tissue sections imaged for GL-II-93 in reflectron MSMS mode, for the
transition of the parent 416>357.

The GL-II-93 is structurally similar to SH-053-2’F-R-CH3 acid, having the same core
imidazobenzodiazepine scaffold and pendant phenyl ring (Figure 80). However, there is a
difference in electron density due to the variance in the functional groups present. Gl-II-93 has
a bromine instead of an acetylene substituent. Unfortunately, a simple washing step did not
prove effective for Gl-II-93 to remove interferences and generate better images.

Figure 80. Structure of GL-II-93 and SH-053-2’F-R-CH3 acid.

The solution for this particular sample preparation challenge lied in the selection of
matrix. Although many application work with DHB, each analyte can cocrystallize and ionize
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better or worse depending on the matrix selected. Shifting from DHB to DHAP showed a
significant improvement in the image for GL-II-93 as seen in Figure 81.

Figure 81. Images for GL-II-93 with dihydroxybenzoic acid (416>237), and with dihydroxyacetophenone
(416 parent viewed in MSMS mode) as the matrix, respectively

Reproducible fragments were generated for GL-II-93 as well (Figure 82), although the
ion density maps were not as strong as those seen for SH-053-2’F-R-CH3 acid. Figure 83
illustrates a proposed fragmentation pattern seen for the analyte in both ESI-MS and MALDIMS.
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Figure 82. Fragment images for GL-II-93 for 416>331 and 416>370 transitions.

Figure 83. Proposed fragmentation pattern for the GL II 93 compound, for the fragments imaged above.

An important consideration in any analytical method development is the efficiency of a
method. In MALDI-IMS, the spatial resolution of the image can be increased based on the
distance between spots the laser fires upon, as well as the diameter of the laser itself. All
images above were taken at a spatial resolution of 100 micron, with a laser diameter of 100
micron. However, the instrument is capable of smaller diameters for both spatial resolution and
laser diameter. The image in Figure 84 shows the same experimental sample preparation as the
images above, but with the spatial resolution and laser diameter both set to 50 micron instead
of 100 micron.
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Figure 84. GL-II-93 parent compound (416 m/z) at 50 micron resolution, for two lobes of lung tissue.

The resolution is greatly improved with the 50 micron resolution and good distribution
of GL-II-93 is detected throughout the tissue. However, the analysis time and data file size was
also significantly larger. For the acquired image analysis above the analysis time doubled.
Therefore it is important to determine if the information gained from a higher resolution (and
longer lasting) experiment is really more significant than that of a lower resolution experiment.
One does not necessarily need to keep the spatial resolution and laser diameter the same,
however. It is possible to “oversample” and have a laser diameter larger than the diameter of
the laser, therefore rastering across parts of the tissue twice and potentially ionizing even more
sample. An example of this “oversampling” technique is shown with the images in Figure 85.
The spatial resolution is decreased while the laser diameter is held constant.
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Figure 85. Samples imaged at 70 micron and 80 micron spatial resolution, respectively, with the laser
diameter held at 100 micron. Left image is GL-II-93 416>373, right image is SH-053-2’F-R-CH3 acid
360>283. H&E stain is also pictured at zero magnification, which correlates with the SH section.

By moving the sample target a distance that is less than the diameter of the laser beam,
image resolution is enhanced, as more of the sample is ablated. Ideally the MALDI matrix is
applied sufficiently wet so that the analyte within the sample is incorporate into the matrix, but
must dry rapidly enough to minimize migration within the tissue sample. In addition to this,
complete ablation of the sample is desired, to consistently acquire the maximum amount of
signal possible.57

7.3.2 MALDI results in MS1 mode
MALDI IMS can also be used as an investigative tool to gain insight into potential
metabolites generated in vivo, since all of the samples imaged are from lungs of mice dosed
with GL-II-93.
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In addition, to use MALDI IMS in the reflecton MS/MS mode, which results in high
specificity towards an analyte of interest, the MS1 mode (linear mode) can be used to
investigate adducts generated in vivo, or metabolites within the tissue sample. In reflectron
MS/MS mode, ion gating only allows the parent mass (defined by a specified range) to be
fragmented and analysis by the second flight tube. Therefore, adducts or metabolites that have
a different mass will be exclude. The MS1 mode however, will enable the quantification of
distinct masses defined by a specific mass range, such as in Figure 86, which depicts the mass of
436 m/z which corresponds to GL-II-93 + Na+.

Figure 86. The GL-II-93+Na+ imaged in a lung tissue section.

Another strong ion 203 m/z was detected in the MS1 mode and quantified by MALDI
IMS. This mass was absent in the lung tissue from non-treated mice thus it strongly suggest that
it might be a metabolite of GL-II-93 (Figure 87).
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Figure 87. Unknown metabolite at m/z 203. The top sections show the lung without and with washing to
remove salt interferences. The bottom sections show this mass imaged in undosed lung tissue sections.

Although the structure of the 203m/z ion is not known, it might be interesting to quantify it in
PK samples to determine it’s occurrence in a time dependent manner. To confirm this
compound as an metabolite of GL-II-93, it’s concentration should increased and then decreases
in time similar to parent compound GL-II-93.

7.3.3 Immunohistochemistry results
The results of the immunohistochemistry experiment using a HRP conjugated secondary
antibody for the α5 subunit or the GABAAR are depicted in Figure 88.
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Brown stain surrounding the
airway, possibly the alpha 5
GABAA receptor subunit

Blueish Brown color as
counterstain for general
tissue

Figure 88. HRP stain of lung tissue section, with brown and blue colors.

Figure 88 shows a light brown background stain and a more intensive brown stain for some of
the lung tissue areas. Unfortunately, the blue counter stain of hematoxylin was difficult to
distinguish from the brown tissue stain using a standard light microscopy. Therefore, a
secondary antibody with a fluorescein tag was employed to improve the quality of the
immunohistochemistry picture using fluorescence microscopy rather than light microscopy,
which enables the decrease of background signals (Figure 89). For immunofluorescence, the
tissue counterstain is imaged in a different channel than the antibody conjugate. Therefore the
overlap issue is eliminated.
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Figure 89. Positively and negatively (without primary antibody for α5 GABAAR subunit) stained
lung airways imaged with a FITC conjugated secondary antibody.

Although the positive image (left) appears brighter than the negative control, a better
resolution is necessary to confirm staining of the α5 GABAAR subunit in lung tissue. These
pictures were taken with an Evos AMG fluorescence microscope (Frick lab, Department of
Chemistry & Biochemistry, UWM). However, while improving this procedure the imaging was
transferred to a Nikon inverted fluorescence microscope (Steeber lab, Department of Biological
Sciences, UWM) which provided significantly improved image quality. We also substituted the
FITC conjugated secondary antibody for a Cy5 conjugated secondary antibody. The resulting
images are shown in Figure 90.

125

Figure 90. Positively stained mouse airway sections, imaged with Cy5 fluorescence at 200x
magnification.

Staining for the α5 GABAAR subunit was clearly observed with relatively intense staining
around the lung airways that consist of epithelial cells and smooth muscle cells. Although the
Nikon microscope produces black and white images, the level of background and signal can be
matched between samples for comparison. The images can also be colored after the fact, which
can aid in the overlay of multiple images if necessary. A comparison between positive and
negative staining is provided in Figure 91.
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Figure 89. Mouse lung airways stained with the Cy5 probe at the alpha 5 receptor (positive staining and
negative control). Image on the top represents a positive airway stain, original black and white color.The
image presented on the left is the same as the previous figure, however the pseudocoloring
functionality has been employed on the microscope to show the positive staining as a red color.
Negative controls were conducted by omission of the primary antibody.

In order to establish a comparison between positive and negative sections, it is desirable
to compare similar morphologies. In this work, the airway is the morphology of specific interest.
Therefore, during the imaging process, airways were first identified using a DAPI stain, to
ensure that the morphologies being compared were correct ones. An example is given in Figure
90.
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Figure 90. DAPI stain of lung tissue, showing two airways.

Once the morphology of the airway was identified, the tissue slice was imaged with fluorescent
light to visualize the location of the α5 GABAAR subunit. The above immunological stains were
taken from serial sections to the following, which was concurrently analyzed by MALDI IMS.

Figure 91. Serial section of lung tissue imaged for the SH-053-2’F-R-CH3 acid. The IHC images in Error!
Reference source not found. were taken from a serial section of this lung sample, indicating the
presence of both the alpha 5 GABAAR subunit and SH-053-2’F-R-CH3 acid in the same lung.
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In addition, brain tissue was used as a positive control for the immunohistochemistry
protocol because the expression of the alpha 5 GABAAR subunit has been reported for the
brain.58

Figure 92. Mouse brain sections stained for alpha 5 GABAAR subunit. The left section was a negative
control by omission of the primary antibody. For the right image the primary antibody was added.

Finally all four imaging techniques (immunohistochemistry, MALDI IMS, H&E and
confocal microscopy) were combined from four consecutive slices from a mouse lung (Figure
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95).

Figure 93. Mouse lung serial sections including overall ion density map, correlating H&E stain at 100x
magnification, and Cy5 IHC at 200x magnification.

These images show good correlation between the location of the compound of interest in the
MALDI IMS data, the IHC tissue stain, and the H&E stained tissue, all taken in serial fashion. The
current obstacle with this multi-modal comparison lies in the varying magnification levels that
generate optimum data for each method. While H&E stains can be viewed at any magnification,
the immunofluorescence is only seen when the magnification is at 200x. The fluorescence
signal can be somewhat visualized at 100x, but the resolution makes localization difficult. The
MALDI IMS image resolution can be increased and therefore “zoomed in” if the images were
taken with a higher spatial resolution image (the instrument can go as low as 10 μm), however
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at the time of this work, the instrument was experiencing technical limitations which made
imaging experiments lower than 50 μm impossible. This issue is currently being resolved by the
MIDD.
7.4

Conclusions

We have shown the ability to image small molecules in different tissue samples by MALDIMS/MS, which is a technique on the forefront of drug discovery today. The 7090 Shimadzu
instrument, however, has limitations with regard to the quality of images that can be
generated. Major limitations are regarding the laser diameter and spatial resolution. An
important compromise was made for imaging experiments, as the more data points acquired
equates to longer analysis time. The image resolution can actually be predictively increased
using image fusion software, which combines the spectra from the MALDI with an image taken
from a histological stain (acquired with a light microscope) and relates these images to predict,
with greater resolution, where the analyte is located.59
Closing Remarks
Metabolic assays such as liver microsome stability and brain homogenate metabolism give us
an indication of about the in vivo stability of a drug, which enables early stage rule-outs for
some drug candidates. This is no trivial task, as medicinal chemists typically synthesize dozens if
not hundreds of analogs around a particular lead compound, and high throughput screening
methods are necessary to hone in on the most viable drug candidates. In vitro assays enable us
to choose the best lead compounds to move forward with in vivo studies. Pharmacokinetic
studies are not high throughput assays, rather they are time consuming and expensive.
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However, these assays are paramount to gather more information about ADME and
formulation. Absolute compound quantitation verifies the presence or absence within real
biological samples. Low limits of detection were achieved using a triple quad LC-MS/MS at
UWM. Without the low limits of detection offered by LC-MS/MS analysis, later time points of a
PK study would be challenging to quantify, which would make the calculation of PK parameter
such as clearance more difficult. Prior to the development of these methods researchers at
UWM were forced to hire an outside CRO for these studies (contract research organization).
Based on this analysis, we were able to show by MALDI IMS where within that target tissue a
compound was located. MALDI-IMS is an exciting field in mass spectrometry with new
applications still emerging.
In the future, MIDD investigators can combine pharmacokinetics studies and mass
spectrometry imaging. We have not yet attempted this method, and it is actually a
controversial approach as MALDI is generally thought to be a semi-quantitative method.
Without standards, quantification based on desorption and ionization is not reliable. In
addition, complex matrix effects seen with in vivo samples, such as tissue slice thickness,
further complicate the separation of ions and the ability to quantify. Other research groups are
attempting to tackle this issue by using different internal and external standard methods.53, 60
This is an interesting potential future direction because it would offer the ability to combine
two experiments into one, quantifying the amount of compound in the tissue and also showing
the localization of this compound at the same time.
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Another important future direction for the MIDD lies in high resolution mass spectrometry and
its application in metabolomics. IT-TOF provides high resolution capabilities in LC-MS/MS, and
compounds can be fragmented multiple times to elucidate structures. Our current approach
creates metabolites in vitro, with the microsome assay, and in vivo, with PK studies. One
particular metabolite, XHE-III-74 acid, has been shown specificity for the alpha 4 GABAAR
subunit and is generated in vivo from the precursor, XHE-III-74 ethyl ester. This metabolite was
discovered using a unit resolution quadrupole instrument, which is less ideal for metabolomics.
However, the IT-TOF possesses formula prediction software in addition to the MSn
fragmentation capabilities. Therefore it is the ideal instrument to continue investigation of both
active and non-active metabolites. In addition, once robust methods for metabolite
identification are established, excretion samples could be collected and investigated. Phase II
metabolites would be of high interest here. Blood or other tissue samples could be further
investigated to look for pro-drug possibilities. HRMS is an incredible tool for metabolite
identification and we are mere steps away from exploring this field within the Arnold Group
embedded in the MIDD.
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Appendix A: MRM parameters for α5β3γ2 selective ligands

Compound
Name
MP II 069

Precursor
m/z
383.20

MP II 068

371.20

HZ 166

356.90

MP III 024

343.20

Diazepam

285.20

MP III 004

373.95

MP IV 004

397.9

MP024 HZ acid

328.9

SH-053 2'F

373.9

MP IV 062

267.95

SH053 RS CH3

388

Nordiazepam

276.05

Product
m/z
339.20
329.30
311.20
329.00
311.00
285.10
232.10
311.15
283.15
282.15
311.00
283.00
256.00
241.00
222.10
193.10
154.10
342.05
314.25
273.00
340.10
356.85
220.70
297.05
99.10
265.00
327.95
299.95
273.05
240.10
144.05
123.05
342.05
249.10
315.00
301.00
213.00

Dwell
time
20.0
20.0
20.0
20.0
20.0
20.0
20.0
35.0
35.0
35.0
20.0
20.0
20.0
30.0
30.0
30.0
30.0
30.0
30.0
30.0
100.0
100.0
100.0
30.0
30.0
30.0
30.0
30.0
30.0
30.0
30.0
30.0
100.0
30.0
30.0
100.0
10.0

Q1 pre
bias (V)
-13.0
-23.0
-24.0
-23
-23
-23
-23
-17
-17
-17
-21
-22
-17
-18
-19
-19
-18
-25
-25
-25
-26
-26
-26
-22
-22
-22
-18
-18
-18
-29
-29
-29
-19
-19
-19
-19
-19
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Collision
Energy
-13.0
-16.0
-22.0
-15
-23.0
-21.0
-29
-20
-31
-39
-20
-30
-37
-37
-27
-33
-27
-18
-30
-40
-23
-9
-30
-8
-21
-7
-20
-34
-40
-11
-20
-24
-20
-35
-35
-30
-30

Q3 Pre
Bias (V)
-21.0
-30.0
-10.0
-21
-30.0
-30.0
-23
-30
-18
-28
-30
-12
-26
-22
-22
-29
-25
-22
-29
-26
-36
-40
-34
-30
-21
-28
-30
-29
-27
-24
-28
-20
-21
-20
-20
-19
-22

Structure

GL-II-93

413.9

SH-053 2'F R/S
CH3
Acid

360

139.95
164.90
396
368
355.05
302.95
326.8
276.05
248.2
168.1

10.0
10.0
100
100
100
100
100
100
100
100

-19
-19
-20
-30
-30
-28
-30
-30
-30
-38

-30
-35
-18
-35
-29
-30
-44
-34
-41
-43

-22
-22
-24
-20
-36
-32
-32
-28
-26
-28

342.1
316
301.1
249.05
219.9

100
100
100
100
100

-24
-24
-24
-24
-24

-16
-17
-29
-28
-41

-22
-34
-30
-26
-40
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Appendix B: MRM parameters for α4β3γ2 selective ligands

Compound Name
Xhe III 74 EE

Precursor
m/z
342.00

Xhe III 74 Acid

313.90

Xhe III 74 (TBE)

370.00

MRS-01-64

326.8

MRS-01-67

357.7

MRS-01-36

355.7

CMD-45

356

MRS-01-66

340.85

RJ-02-50

328.05

Xhe Acid OCD3

316.9

Xhe EE OCD3
RJ-02-46

345.05

Product
m/z
296.15
278.15
268.15
296.05
278.00
108.95

Dwell
time
30.0

Q1 pre
bias (V)
-16.0

100.0
100.0
100.0

338.45
314.20
296.15
149.30
100.4
296
278.1
268.2
227.1
247.1
296.2
278.2
290.4
296.15
216.5
120.8
300.15
282.1
227.4
296.05
277.95
268.1
227.15
282.05
192.9
264.1
299.05
281
111.95
298.55
281.15

35.0
35.0
35.0
30.0
100
100
100
100
100
100
30
30
30
30
30
30
35
35
35
100
100
100
100
100
100
100
100
100
100
100
100
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-23
-23
-23

Collision
Energy
-19.0
-28.0
-31.0
-16
-26
-40

Q3 Pre
Bias (V)
-30.0
-29.0
-28.0
-30
-28
-25

-18
-18
-18
-17
-36
-36
-38
-36
-36
-36
-17
-17
-17
-17
-17
-17
-17
-17
-17
-40
-40
-40
-40
-16
-16
-16
-20
-20
-20
-22
-22

-9
-13
-22
-30
-38
-19
-27
-29
-36
-38
-15
-27
-32
-21
-35
-30
-11
-22
-40
-20
-20
-20
-20
-20
-19
-30
-16
-26
-40
-18
-28

-15
-20
-30
-20
-40
-30
-28
-26
-40
-22
-30
-29
-21
-30
-12
-18
-30
-28
-15
-30
-30
-30
-30
-18
-25
-16
-20
-20
-20
-28
-28

Structure

Xhe TBE OCD3
RJ-02-52
MRS 01 68

299.15
281.1
271.1
328
328
328
328
328

271.15
299.15
281.1
271.1
296.1
277.95
268.05
250.95
227.1

100
100
100
100
100
100
100
100
100
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-22
-24
-20
-20
-22
-36
-36
-36
-36

-31
-22
-34
-36
-18
-29
-31
-37
-36

-26
-30
-28
-26
-30
-28
-26
-40
-36

Appendix C: MRMs for non-benzodiazepine compounds

Compound Name
GABA

Precursor
m/z
104.10

4,6-diphenyl N OH pyridone

264

pBBG

614

pBBG Diacid

477.95

Verapamil

454.7

MeGFN

302.9

Product
m/z
87.10
86.10
69.20
218.15
247.05
218.95
416.80
331.90
245.90
170.80
170.95
348.95
332.00
165.15
150.20
303.30

Dwell
time
100.0
100.0
100.0
30
30
30
30
30
30
30
30
30
30
100
100
100

Q1 pre
bias (V)
-22.0
-22.0
-22.0
-30
-13
-19
-32
-32
-32
-32
-34
-34
-34
-22
-22
-22

Collision
Energy
-15.0
-15.0
-10.0
-22
-21
-31
-19
-26
-34
-48
-37
-15
-18
-30
-29
-43

Q3 Pre
Bias (V)
-26.0
-28.0
-26.0
-21
-14
-21
-27
-21

271.05

100

19

15

27
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-24
-27
-30
-38
-34
-28
-30
-26

Structure
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